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ABSTRACT 
Filamin A (FLNA) is a large actin-binding cytoskeletal protein that stabilizes actin networks and 
integrates them with cell membranes. FLNA is therefore important for cell motility and organ 
development. We recently discovered that a C-terminal fragment of FLNA (FLNACT) can be 
cleaved off by calpain and stimulate angiogenesis by transporting transcription factors into the 
nucleus. However, little is known about the role of FLNA in cell types that participate in the 
pathogenesis of vascular diseases where angiogenesis typically plays an important role. In this 
thesis, we defined the impact of inactivating Flna in mouse vascular endothelial cells and 
macrophages on the pathogenesis of myocardial infarction (MI) and atherosclerosis, 
respectively—and made several exciting discoveries. 
In Study I, we induced MI by ligating the left descending coronary artery in wt control mice and 
mice lacking FLNA in endothelial cells. The Flna-knockout mice developed larger MI lesions than 
controls, and exhibited larger and thinner left ventricles, impaired cardiac function, elevated 
plasma levels of the cardiac damage biomarker NT-proBNP, and reduced plasma levels of the 
angiogenesis-promoting factor VEGF-A. Hearts from the Flna-knockout mice exhibited reduced 
capillary structures within infarcted regions; and cultured Flna-deficient endothelial cells showed 
impaired migration and tubular formation, along with reduced levels of the signaling molecules p-
ERK and p-AKT and the small GTPase RAC1.    
In Study II, we first discovered that FLNA expression was higher in human carotid arteries with 
advanced atherosclerotic plaques than with intermediate plaques. We generated mice lacking 
FLNA in macrophages and found that their macrophages proliferated and migrated less compared 
with littermate controls. Moreover, Flna-deficient macrophages exhibited reduced levels of p-
ERK and p-AKT, and reduced lipid uptake and increased cholesterol efflux. In two different mouse 
atherosclerosis models, the knockout of FLNA in macrophages markedly reduced lesion size and 
number of CD68-positive lesional macrophages. Interestingly, the calpain-cleaved FLNACT 
fragment interacted strongly with STAT3 in wt macrophages. Inhibiting FLNA cleavage with the 
calpain inhibitor calpeptin reduced nuclear p-STAT3 levels and subsequent IL-6 secretion in vitro; 
and reduced atherosclerotic lesions in vivo. 
We conclude that FLNA interacts with transcription factors and thereby regulates angiogenesis 
and inflammatory responses which are important events in the progression of MI and 
atherosclerosis. These findings identify FLNA as an important new mediator of cardiovascular 
remodeling and as a potential target for therapy. 
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 Betydelsen av Filamin A  
för Remodellering vid Hjärt-kärlsjukdomar 
   Sashidhar Bandaru 
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Sahlgrenska akademin, Göteborgs universitet 
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SAMMANFATTNING 
Vid hjärt-kärlsjukdomar kan skador påverka kroppens kärlceller vilket under läkeprocessen leder 
till nybildning av blodkärl — en process som kallas angiogenes. Att styra angiogenes med 
läkemedel eller andra strategier skulle ge möjlighet att i högre grad reparera de skador som 
uppkommer vid t.ex. hjärtinfarkt och åderförfettning. Angiogenes styrs av proteiner som påverkar 
uttrycket av cellernas gener. Vår grupp har upptäckt att ett protein som kallas filamin A (FLNA), 
interagerar med flera av dessa faktorer och om FLNA inte fungerar under fosterutvecklingen leder 
det till hög dödlighet på grund av försämrad angiogenes. 
Målsättningen med studierna i denna avhandling var att ta reda på om FLNA i blodkärlsceller kan 
stimulera nybildning av blodkärl efter hjärtinfarkt och att avgöra om hämning av FLNA i den 
inflammatoriska celltypen makrofager kan minska utvecklingen av åderförfettning. 
Uttrycket av FLNA har studerats i humana vävnader som har varit utsatta för hjärtinfarkt och 
halspulsåderateroskleros. Möss som saknar FLNA i kärlets endotelceller har studerats för 
angiogenes efter hjärtinfarkt eller makrofager för cellfunktion vid utvecklandet av åderförfettning. 
I odlade celler från dessa möss och i humana celler, i vilka uttrycket av FLNA är blockerat, har vi 
jämfört cellens förmåga att föröka sig, vandra, bilda nya blodkärl, utsöndra cytokiner och ta upp 
fett. Blockering av FLNA i endotelceller ledde till minskad celltillväxt och migrering, och minskad 
nybildning av kärl i odlade celler, vilket ledde till större infarktvolym och förvärrad hjärtsvikt hos 
möss. Avsaknad av FLNA i makrofager ledde till försämrad cellmigrering, utsöndring av anti-
inflammatoriska cytokiner samt fettupptagning i odlade makrofager och således ledde till mindre 
aterosklerotiska fettplack hos möss. Vi har identifierat signalmolekyler eller transkriptionsfaktorer 
som regleras av FLNA-proteinet, vilket ger möjlighet till utveckling av nya, riktade behandlingar. 
Vi har även upptäckt att spjälkning av FLNA med enzymet calpain har betydelse för 
makrofagfunktionen. Vid kemisk hämning av detta enzym utvecklade möss mindre 
aterosklerotiska fettplack. 
Betydelsen av FLNA för hjärtinfarkt och åderförfettning har hittills varit okänd. Kunskapen som 
har genererats i denna avhandling kan få stor betydelse för behandling av allvarliga hjärt-
kärlsjukdomar inom sjukvården. En direkt tillämpning av vår forskning kan vara utveckling av 
nya prognostiska markörer för hjärt-kärlsjukdomar. Dessutom skulle en artificiellt kontrollerad 
angiogenes ge en möjlighet att i större grad reparera de skador som uppkommer vid t.ex. 
hjärtinfarkt, stroke eller accelererad åderförfettning. 
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FILIP  Filamin A interacting protein 1 
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PVNH  Periventricular nodular heterotopia 
PCSK9  Proprotein convertase subtilisin/kexin type-9 
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Filamin A 
The actin cytoskeleton is mainly involved in 
the formation and maintenance of cell shape 
and morphology in response to external 
stimuli from surrounding connective tissue. 
Filamins are one of the actin-binding proteins 
(ABP) that mediate dynamic remodeling 
during cell locomotion. Furthermore, 
filamins are involved in cell signaling and 
transcription. In 1975, the first isoform of 
filamin proteins was discovered and purified 
in macrophages of chicken gizzard [1]. In 
2000, the first splice variant of the filamins 
lacking an actin-binding domain (ABD) was 
identified in Drosophila melanogaster [2]. 
The filamin family comprises three members; 
filamin A (FLNA), filamin B (FLNB) and 
filamin C (FLNC). They all exhibit 70% 
homology with their amino acids and 45% 
homology in hinge 1 (H1) and hinge 2 (H2) 
regions [3]. To date, the most commonly 
studied isoform of filamins is FLNA. Both 
mouse Flna and the human FLNA gene are 
located on the X chromosome. Human FLNB 
and FLNC genes are located on 
chromosomes 3 and 7 respectively, whereas 
mouse Flnb and Flnc genes are located on 
chromosomes 14 and 6 respectively [4]. 
Although FLNA and FLNB are very similar 
to one another, the nature of mutations and 
clinical phenotypes associated with 
mutations differs. All three filamin isoforms 
are expressed strongly during development 
stages. In adult tissues, FLNA and FLNB are 
ubiquitously expressed throughout the body, 
whereas the expression of FLNC is restricted 
to skeletal and cardiac muscles [4]. 
 
 
 
The long elongated Y-shaped (240–280 kDa) 
polypeptide chain of FLNA can exist in either 
homo- or heterodimers. Each chain of FLNA 
is composed of 24 immunoglobulin (Ig) 
repeats which are separated by two hinge (H1 
and H2) regions, whereas H1 comprises 
between 15–16 Ig-repeats and H2 between 
23–24 Ig-repeats (Figure 1) [5]. These hinge 
regions are calpain sensitive and separate 24 
Ig-repeats into the rod 1 domain which 
comprises 1–15 Ig-repeats, rod 2 comprising 
16-23 Ig-repeats and a dimerization domain 
[6, 7]. Ig 24 is the most C-terminal repeat of 
FLNA (FLNACT), which not only helps to 
mediate the dimerization but also confers the 
Y-shape on the dimeric structure [8]. 
FLNACT is comprised of two filamin 
monomers and these monomers help to 
anchor the F-actin to the cell membrane 
through transmembrane receptors [7]. The 
rod 1 domain is transfixed to F-actin, whereas 
the rod 2 domain does not interact with F-
actin. This allows rod 2 to set itself free and 
interact with multiple protiens involved in 
signal transduction. Most of the protein 
interactions are conferred on the rod 2 
domain due to its free-moving structure [9].  
 
ABD is the key subunit of FLNA, binding to 
F-actin. FLNA dissociates from F-actin due 
to the competitive binding of Ca2+-
calmodulin, which results in the deletion of 
ABD in the FLNA subunit and weakens its 
ability to instigate gelation activity in the 
actin solution [9]. The ABD of FLNA is 
composed of two calponin homology (CH) 
domains, known as CH1 and CH2, which are 
separated by a linker. This organization of 
CH domains determines the binding ability of 
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FLNA actin molecules towards F-actin [3]. 
The amino acids from 121–147 in FLNA, 
which corresponds to the CH1 domain, serve 
as a primary binding site for F-actin [10]. The 
amino acid sequence of actin, where FLNA 
binding is conferred, also overlaps with many 
other actin-binding protiens, which sugguests 
that FLNA competes with other actin-binding 
proteins. Upon binding to one another, the 
ABD of FLNA with actin, structural 
reorganization occurs, which could impact 
the shape of F-actin [7]. 
Purified FLNA protein under the electron 
microscope has shown the rod 2 domain as a 
folded structure and rod 1 as an elongated 
chain [11]. The long range of Ig-repeats in the 
rod 1 domain of FLNA provides essential 
flexibility during mechanical stress and Ig-
repeats 9–15 containing ABD provide high-
affinity binding towards F-actin. Ig-repeats 
1–8 in the rod 1 domain are flexible and help 
the 9–15 Ig-repeats to provide the correct 
alignment with actin monomers [7]. Even 
though both rod 1 and rod 2 of FLNA have 
similar numbers of Ig-repeats, the Ig-repeats 
of rod 2 form a compact shape far more than 
those in the rod 1 domain. The binding of 
even numbered repeats to the neighboring 
repeats in FLNA results in a compact, more 
globular structure of rod domains [12, 13]. 
The hinge regions in the human FLNA 
protein have a larger amino acid assortment 
and are also longer, which not only provides 
extra flexibility in sheer stress but also helps 
with binding to actin at a perpendicular angle, 
even though actin is widely spread [14]. The 
hinge regions are proteolyzed by Ca2+-
dependent calpains and the cleavage of these 
sites produces a 90 kDa FLNACT and a 200 
kDa N-terminal fragment (FLNANT) [15].  
Figure 1: Structure of filamin A. FLNA 
homodimers include an N-terminal actin-binding 
domain,  a C-terminal dimerization domain and 
24 Ig-repeats that are interrupted by hinge 1 and 
hinge 2 regions.  
Filamin A in cellular signaling 
Filamin A is a large protein and mainly helps 
to provide scaffolding to its interacting 
partners. Due to the high level of similarity 
between the Ig-repeats, multiple proteins 
bind at multiple sites of FLNA [11]. Other 
than providing a structural organization to 
cells, FLNA protein is also involved in 
various other functions, such as organ 
development, cell signaling, migration, 
proliferation, cell adhesion, phosphorylation, 
transcription and the nuclear transportation of 
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transcriptional factors. Many studies reveal 
that various cellular functions are performed 
by FLNA through its interaction with more 
than 90 proteins [16]. FLNA is found to be 
co-localized with tissue factor (TF), which is 
also regarded as a ligand to the cytoplasmic 
domain of TF [17]. The absence of interacted 
FLNA–TF might be one of the causes of 
embryonic lethality in Flna-deficient mice, 
due to the incomplete implantation of the 
embryo into the endometrium and the 
covering of the location with a fibrin plug 
[18]. FLNA promotes platelet adhesion by 
interacting with glycoprotein-Ibα (GPIbα) 
[19]. Studies have shown that FLNA is also 
associated with the regulation of cell cycles. 
Flna-deficient mouse embryos exhibit a 
smaller brain size and fewer neuronal 
progenitors, which contribute to a prolonged 
cell cycle [20]. This prolonged cell cycle 
occurs mainly in the M phase, due to the 
interaction of FLNA with CDK1 kinase and 
WEE1. In the absence of FLNA, the 
phosphorylation of CDK1 kinase is 
increased, resulting in a prolonged cell cycle 
[20]. 
There are a few protein interactions which 
can alter the expression and functionality of 
the FLNA protein. The interaction of FLNA 
with FLNA-interacting protein (FILIP) 
promotes cortical radial cell migration from 
the ventricular zone [21]. When FLNA is 
overexpressed in cells silenced for FILIP by 
siRNA, it regulates cell polarity in 
intermediate and subventricular zones in the 
neo cortex [22]. FLNA binding with the 
ADP-ribosylation factor, guanine exchange 
factor 2 (ARFGEF2), transports FLNA to the 
cell surface in neuronal progenitors and the 
silencing of ARFGEF2 inhibits the transport 
of FLNA in the Golgi apparatus [23]. FLNA 
interacts with REFILINB and forms a 
complex. This complex organizes perinuclear 
actin bundles by forming an actin cap. The 
FLNA ̶ REFILINB complex is also able to 
alter its nuclear shape during epithelial-
mesenchymal transition [24]. FLNA 
interaction with MEKK4 is also important to 
promote neuronal migration. Like FLNA 
human mutation, MEKK4-deficient mice 
develop PVNH and FLNA expression levels 
that are more elevated in the forebrain in 
these mice [25]. Interaction with cyclin D1 of 
FLNA promotes breast cancer cell migration 
and invasiveness [26]. FLNA binding to the 
androgen receptor (AR) helps the nuclear 
localization of AR and inactivates AR protein 
when it enters the nucleus [27]. This FLNA–
AR interaction may also promote cancer 
progression in prostate cancer [28]. FLNA 
interaction with BRCA2 helps to provide 
scaffolding to BRCA2 during the assembly 
of DNA repair [29]. Phosphorylated ERK (p-
ERK) binds at FLNACT. This interaction 
regulates endoplasmic reticulum and plasma 
membrane towards the contact sites. 
Interestingly, the deletion of FLNA results in 
F-actin cytoskeleton modification from
homogeneous to cortical distribution,
whereas the absence of p-ERK leads to more
enrichment of FLNA in plasma membrane
[30]. In our previous studies, we have
observed a decrease in lung tumor size in an
Flna-deficient mouse model, despite the
constitutive expression of KRAS. Our in-
vitro studies indicated that Flna-deficient
KRAS-transformed fibroblasts proliferate and
migrate poorly. These cells also express
lower phosphorylated levels of both AKT
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and ERK1/2 [31]. We also observed similar 
results in mice that are deficient in FLNA 
specifically in endothelial cells. In these 
studies, both cell migration and the size of 
tumor xenografts are reduced, due to the 
absence of endothelial FLNA. In-vitro 
studies have also shown defects in 
endothelial cell migration that might be due 
to lower levels of p-AKT and p-ERK1/2 [31]. 
FLNA interaction with the SPHK1-
interacting protein induces cell migration, 
lamellipodia formation and FLNA 
phosphorylation in A7 melanoma cells [32]. 
FLNA expression negatively regulates 
sphingosine-1-phosphate and NF-κB 
activation in FLNA-deficient M2 melanoma 
cells [33]. In these cells, RelA (p65) is 
phosphorylated to a greater degree, resulting 
in the activation of NF-κB protein. NF-κB is 
regarded as the key regulator for many of the 
inflammatory responses [33]. FLNA also 
interacts with the ring zinc finger domain of 
tumor necrosis factor receptor-associated 
factor 2 (TRAF2). TRAF2 is thought to 
negatively suppress the activation of NF-κB 
via the JNK/SAPK pathway [34]. When 
FLNA is epitopically overexpressed in 
FLNA-deficient M2 cells, TRAF2 is silenced 
and the JNK/SAPK pathway is induced, 
resulting in the activation of NF-κB in M2 
cells [34]. This suggests that FLNA controls 
various signaling pathways leading to 
inflammatory responses. 
Filamin A in cellular migration 
Cell migration is regarded as the crucial step 
during embryogenesis, wound healing and 
also pathological processes, such as immune 
responses, tumor formation and metastasis. 
All these processes require the specific 
movement of particular cells to designated 
locations. Cell migration is a schematic 
process which is involved in cell polarization, 
protrusion in the direction of cell movement, 
retraction and release from the rear. FLNA is 
present in most motile cells at both the 
leading and rear end. FLNA has been shown 
to be involved in the remodeling of the actin 
cytoskeleton and cell protrusion and 
retraction.  
FLNA is involved in the organization of actin 
filaments to the cell membranes, which helps 
to provide scaffolding for multiple 
cytoskeletal proteins by the integration of cell 
adhesion [3, 6]. The immunofluorescent 
staining of cultured cells indicates that FLNA 
is more localized to lamellipodia, filopodia, 
stress fibers and focal adhesions [35]. The 
possible suggested mechanisms behind these 
processes could be the specific binding 
partners of FLNA, such as receptors and 
adhesion molecules that mostly reside in the 
cell region under movement [36]. Another 
possible explanation could be higher 
concentrations of FLNA in newly assembled 
actin sites in lamellipodia, due to greater 
avidity for the branched F-actin junctions [9, 
37]. 
FLNA is more concentrated towards adjacent 
sites to the cell membrane during cell spread 
[38] and subsequently towards adhesion sites
when force is applied [39]. This indicates the
importance of FLNA in regulating the
strength of cell adhesions and the process of
cell adhesion. FLNB is mostly associated
with stress fibers and does not localize to
focal adhesions like the FLNA isoform.
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Since the discovery of FLNA in 1975, FLNA 
binding partners have been increasing at a 
steady pace and there are now more than 90 
binding partners, in addition to an association 
with actin filaments [5]. The majority of the 
interacting partners play a significant role in 
regulating cell adhesion, migration and cell 
spread [40]. In the first case report on FLNA 
mutations, an association with periventricular 
nodular heterotopia (PVNH) was reported 
[41]. Subsequently, multiple studies have 
focused more heavily on FLNA function in 
neuronal migration, as mutations in FLNA 
prevent the migration of cortical neurons in 
PVNH. Interestingly, the overexpression of 
FLNA also prevents neuronal migration [25]. 
However, Flna-deficient mice do not develop 
PVNH and even the embryonic fibroblasts do 
not display any defects in cell migration and 
growth [18, 42]. This might be due to small 
brain volume, less complex than that in 
humans. However, these mouse embryos 
exhibit a thinner cerebral cortex, indicating 
defects in cell migration [18]. 
Interaction partners of filamin A 
Integrins 
The majority of the cells migrate in an 
integrin-dependent manner, even though 
certain cell types migrate in an integrin-
independent manner without binding to 
integrin [43] and swim independently [44]. 
The relationship between the FLNA and 
integrins is mutual. When mechanical stress 
is conveyed by integrin β1, it recruits FLNA 
and F-actin towards focal adhesions which 
contain integrin β1 [39]. FLNA is well 
situated in the cell, mediating the matrix-
cytoskeletal signaling with its dual binding 
capability. F-actin binds at FLNANT, 
whereas various transmembrane adhesion 
receptors and integrins bind at FLNACT. 
Integrin β1 binds at Ig-repeats 16–24 of 
FLNA to regulate endothelial cell motility 
[45]. Integrin β2 binding at repeat Ig-21 
mediates leukocyte extravasation [46]. The 
binding of integrin β3 at repeat Ig-21 
promotes platelet aggregation. The binding 
of integrin β7 at Ig-repeats 19–21 mediates 
lymphocyte migration [47]. 
Interestingly, FLNA has also been reported 
as a negative regulator of integrins. The 
depletion of FLNA reduces the cell surface 
expression of integrin β1. In FLNA-deficient 
cells, the cell surface expression of integrin 
β1 is reduced during the initial 15 minutes of 
cell contact. Once FLNA expression is 
restored in these cells, integrin β1 expression 
is rescued as well [48]. During mechanical 
stress, integrin β1 recruits both F-actin and 
FLNA towards focal adhesions where 
integrin β1 is present [49, 50]. Integrin β1 also 
improves FLNA promoter activity and 
prolongs FLNA mRNA half-life by 
selectively activating the p38 pathway in 
fibroblasts [51]. In contrast, the inactivation 
of integrin β1 function reduces FLNA 
expression in the localization and spread 
towards cell membranes. Reciprocally, the 
loss of FLNA function reduces the 
endogenous expression of integrin β1 in 
human breast cancer cells [52], thereby 
increasing tumor invasiveness [53]. The 
silencing of FLNA increases calpain activity, 
leading to the turnover of focal adhesions, 
which may result in inducing tumor 
invasiveness [54, 55]. Furthermore, integrin 
 20 
β1 trafficking to the cell membrane is 
regulated by the PKCε-mediated 
phosphorylation of vimentin [56], which is 
known to bind at Ig-repeats 1–8 of FLNA. 
The silencing of FLNA mRNA in culture 
cells impairs vimentin phosphorylation, 
leading to reduced cell adhesion and spread. 
This impaired cell spread is rescued by 
transfecting FLNA-deficient cells with Ig-
repeats 1–8 alone, without complete ABD 
[56].  
 
Even though the binding of FLNA to 
integrins is necessary for cell spread and 
migration, either too much or too little 
binding results in impaired migration and cell 
spread. Cell migration and adhesion are fine-
tuning processes between two proteins and 
other integrin-binding partners. 
 
GTPases 
In mammalian cells, small GTPases regulate 
the generation of actin-based motile 
structures. Small GTPases are activated when 
intregrins bind to the extracellular matrix, 
resulting in actin polymerization and the 
formation of lamellipodia and filopodia. 
Branched actin networks are the key 
ingredients in the formation of lamellipodia, 
which drive the cells to move forward. FLNA 
interacts with RalA and small GTPases, 
including Rho, Rac and Cdc42. FLNA 
interacts with the majority of the upstream- 
and downstream-signaling molecules of 
GTPases. The majority of interactions occur 
in the FLNACT region at Ig-repeats 23–24 
[57]. In FLNA-deficient melanoma cells, 
RalA fails to generate filopodia and, when 
FLNA is reintroduced by transfection, 
filopodium has been generated in these cells. 
This suggests that RalA may recruit FLNA to 
filopodium to regulate RalA-mediated 
filopodial protrusion [57]. FLNA interacts 
with PAK1, which in turn activates PAK1 
and phosphorylates FLNA, as the activation 
of PAK1 is necessary for membrane ruffling 
[58]. Another pathway to activate PAK1 is by 
binding to sphingosine kinase 1. The 
interaction between FLNA and sphingosine 
kinase 1 activates a potent lipid meditator, 
sphingosine-1-phosphate, which directly 
activates PAK1 kinase activity [32]. PAK1 is 
a downstream effector for both Rac1 and 
Cdc42. FLNA also coordinates the Rac GEF 
trio [36] and Rho GEF Lbc [59]. This 
coordination supports the spatial positioning 
of actin assembly. FLNA interacts with 
FilGAP and this interaction may inactivate 
Rac and promote cell retraction by 
suppressing leading edge protrusion [60]. To 
summarize, FLNA anchors GTPase signaling 
to cell membrane proximity where it converts 
from GDP to GTP to provide scaffolding and 
coordinate actin remodeling activities.  
 
 
Transcriptional factors 
Recent studies indicate that FLNA is 
involved in transcriptional activity, either by 
regulating transcriptional activity by 
activating the transcriptional factors or by the 
repression of transcriptional factors by 
retaining them in the cytoplasm. The majority 
of transcriptional factor interactions take 
place in the FLNACT region. FLNA interacts 
with SMAD2 and SMAD5, positively 
inducing the receptor-induced 
phosphorylation of SMAD2 and SMAD5, as 
well as nuclear accumulation [61]. However, 
the interaction of FLNA with PEBP2β/CBFβ, 
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the subunit of PEBP2/CBF transcriptional 
factors, inhibits the binding ability of this 
complex to RUNX1 [62] or binding to 
another transcriptional regulator, p73 [63]. 
This interaction represses transcriptional 
activity and retains it in the cytoplasm of 
human melanoma cells [63]. FLNA may also 
participate in the DNA damage-response 
pathways by interacting with the tumor 
suppressor gene, BRCA2, in HeLa cells [64]. 
It has previously been demonstrated that the 
transcriptional activity of FOXC1 is 
mediated by the interaction of FLNA with 
PBX1. PBX1 interacts with the full-length 
FLNA protein efficiently to transport PBX1 
to the nucleus, where it forms a 
transcriptional inhibitory complex with 
FOXC1 ̶ PBX1 in A7 melanoma cells [65]. 
Recent studies indicate that FLNA is 
involved in the nuclear localization of 
transcriptional factors, but studies are still not 
complete. In androgen-dependent prostate 
cancer cells, FLNA is cleaved by calpains, 
producing a 90 kDA FLNACT fragment. It is 
then localized to the nucleus. However, in 
androgen-independent cells, FLNA remains 
in the cytoplasm and fails to be cleaved by 
calpains [66]. Consistent findings indicate 
that FLNA is cleaved by calpains, resulting 
in the production of FLNACT. This fragment 
is involved in the nuclear transportation of 
the androgen receptor (AR). Along with AR 
in the nucleus, FLNACT represses the 
transcriptional activity of AR by interfering 
with interdomains and the co-activator 
binding site of AR [27, 67]. FLNA 
interaction with transcriptional factors in 
general may thus promote cell movement by 
inducing the expression of growth factors by 
either autocrine or paracrine signaling.   
In our previous studies, we have reported a 
novel interaction between FLNA and the 
hypoxia-inducible factor-1α (HIF-1α). When 
mammalian cells are exposed to lower 
oxygen levels, HIF-1α helps them to adapt to 
hypoxic conditions [68] by activating a 
varying network of target genes [69]. During 
normoxia, HIF-1α protein is degraded by a 
tumor suppressor, protein von Hippel-
Lindau, acting as an E3 ubiquitin ligase and 
hydroxylation near-proline residues [70]. 
During hypoxia, hydroxylation is inhibited, 
resulting in the stabilization of HIF-1α, 
which then translocates into the nucleus and 
activates its target genes, including vascular 
endothelial growth factor-A (VEGF-A) [71]. 
We have reported that a cleaved FLNACT 
fragment promotes the transcriptional 
activity of HIF-1α by facilitating nuclear 
translocation and induces the secretion of 
VEGF-A [72]. In our Study I, we observed 
lower serum levels of secreted VEGF-A in 
mice deficient in FLNA in endothelial cells 
after a myocardial infarction (MI). We have 
observed more scar tissue and an enlarged 
heart in these mice, which indicate Flna 
deficiency in endothelial cells which then fail 
to generate new blood vessels around the 
infarcted cardiac muscle. This could be one 
reason why the infarction size increases in 
mice deficient in Flna in endothelial cells. 
FLNA has the potential to regulate 
transmembrane receptor expression, by 
interacting with transcriptional factors and 
altering the cell response to various external 
cellular signaling, including growth factors. 
In our previous studies, we have shown that 
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the expression of c-MET is upregulated by 
FLNA, partly by the transcriptional factor, 
SMAD2. FLNA binds to SMAD2 to 
transport it to the nucleus [61], which in turn 
activates c-MET activity by binding to its 
promotor and regulates the cellular response 
to hepatocyte-growth factor (HGF) [73]. 
Mature c-MET receptor is a heterodimeric 
protein consisting of a 45 kDa α-subunit 
which is linked to a 145 kDa β-subunit by 
disulfide bonds [74]. The binding of c-MET 
to HGF triggers multiple phosphorylation 
sites, two in the kinase domain (Tyr1234 and 
Tyr1235) and two at the docking site 
(Tyr1349 and Tyr1356) [74]. Multiple 
signaling molecules and adaptor proteins are 
recruited at the docking site after 
phosphorylation, resulting in the activation of 
signaling cascades and triggering various 
tumorigenic responses, such as scattering, 
invasion, proliferation and branching [75].  
In Study II, we discovered a novel interaction 
between FLNACT and a signal transducer 
and activator of transcription 3 (STAT3). We 
hypothesized that FLNA may likely facilitate 
the nuclear phosphorylation of STAT3 to 
further activate the secretion of the 
inflammatory response cytokine, IL-6. The 
STAT family consists of seven members 
[76]. STAT3 was first discovered in 1993 in 
mammalian cells. The STAT3 protein 
consists of six domains (1, amino-terminus; 
2, coiled coil domain; 3, DNA binding 
domain; 4, linker domain; 5, Src homology 
two domains; and 6, carboxyl-terminal 
transactivation domain). The deficiency of 
STAT3 results in embryonic lethality due to 
severe malformations in the visceral 
endoderm [77], indicating that STAT3 plays 
a vital role in development. STAT3 
activation is mainly dependent on 
phosphorylation at two sites, tyrosine 705 
and serine 727, which reside in the C-
terminus. In response to cytokines IL-5, IL-6 
and IL-10 and the growth hormone, leptin, 
STAT3 phosphorylates the Tyr705 site and is 
then translocated into the nucleus where it 
acts as a transcriptional factor [78]. 
Phosphorylated STAT3 binds directly to the 
γ-interferon site in the DNA promoter regions 
in cooperation with nuclear factors [79, 80].  
STAT3 is widely described as the crucial 
mediator, which controls cell adaptation in 
response to external stimuli in both 
inflammatory cells and non-inflammatory 
cells such as endothelial and smooth-muscle 
cells [81]. STAT3 activity might act as a key 
regulator in mediating angiogenesis after MI 
[82]. The tissue-specific deletion of STAT3 
in cardiomyocytes reduces myocardial 
capillary density in mice [83]. STAT3 is 
more phosphorylated in the atherosclerotic 
plaques of ApoE knockout mice, indicating a 
crucial role for STAT3 during the 
pathogenesis of atherosclerosis [84]. Plasma 
from these mice exhibits higher 
concentrations of circulating IL-6 [85]. 
STAT3 considerably regulates the number of 
cytokines by regulating its transcription in 
macrophages and smooth-muscle cells [81]. 
Crosstalk between vascular smooth-muscle 
cells and monocytes elevates both IL-6 and 
STAT3 expression, resulting in the 
upregulation of multiple cytokines in 
monocytes and enhanced reactive oxygen 
species in vascular smooth-muscle cells. 
These may contribute to the development of 
atherosclerotic plaques [86, 87]. STAT3 
signaling operates in the IL-13 pathway to 
mediate foam cell formation [85]. 
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Calpains and calpain 
inhibitors 
The hinge regions of FLNA (H1 and H2) are 
proteolyzed by Ca2+-dependent calpains. The 
cleavage of these regions produces 90 kDa 
FLNACT and 200 kDa FLNANT [15]. 
Calpains are cysteine proteases that are 
present in the majority of mammalian cells 
and a few bacteria. Calpain in mammalian 
cells generally presents as calcium-
dependent cysteine proteases, which consist 
of 15 isoforms [88]. Among these 15 
isoforms, calpain-1 and calpain-2 are widely 
distributed and are the most studied isoforms 
and they are often referred to as conventional 
calpains [89]. Calpains contain two subunits, 
a small 30 kDa calmodulin-like calcium-
binding unit and a large 80 kDa papain 
protease-like unit [90].  
Calpains participate in various cellular and 
physiologic activities, such as cytoskeletal 
remodeling [91], cell motility, [92], 
embryonic development [93], signal 
transduction pathways [94], apoptosis [95], 
the regulation of gene expression [96] and 
cell cycles [97].  
Apart from physiologic events, calpains are 
also involved in numerous pathologic events, 
which has led to the discovery of calpain 
inhibitors and their potency in therapeutics. 
Calpain inhibitors are generally classified 
into two groups; non-peptide calpain 
inhibitors (5-azolones, carboxamides, 
dihydroxychalcones and α-
mercaptoacrylates) and peptidomimetic 
calpain inhibitors (α-helical inhibitors, 
epoxysuccinate-based inhibitor and 
calpeptin) [98]. 
Therapeutic uses of calpain 
inhibitors 
Calpain inhibitors are used in various 
disorders, including ocular disorders. Calpain 
1 inhibits retinal visual cell regeneration [99] 
and also acts as an anti-cataract agent [100]. 
It has also been shown that the specific 
inhibition of calpains shields arteries, hair, 
skin and kidneys from age-related lesions, as 
well as telomere shortening [98]. Calpain 1 is 
hyperactivated in Alzheimer’s disease, due to 
a calcium overload in susceptible neurons, 
suggesting calpain 1 as a potential target for 
Alzheimer’s disease [101]. Calpain 1 is 
negatively responsible for the regulation of 
erythrocyte deformability and filtration. As a 
result, the inhibition of calpain 1 has been 
proposed as a therapeutic approach to treat 
sickle cell disease [98]. Calpain 3 inhibition 
is beneficial in treating tibial muscular 
dystrophy. Either the overexpression or the 
inhibition of calpain 3 inhibits disease 
progression [102]. It has also been shown that 
the inhibition of calpain 1 inhibits tumor cell 
growth in colorectal cancer [98]. Both 
calpain 1 and calpain 2 are extremely 
abundant in the heart [103]. Despite the 
higher concentrations of calpains detected 
during ischemic and reperfusion injury [104], 
calpain inhibitors in cardiovascular diseases 
(CVD) have not been studied in detail.  
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Mouse models of filamin A 
deficiency 
The discovery of FLNA-deficient melanoma 
cells has prompted huge interest in exploring 
the cellular functions and interacting partners 
of FLNA in far greater detail. Seven human 
melanoma cell lines have been identified, 
three of which express lower mRNA levels 
for FLNA [105]. All three FLNA-deficient 
cell lines exhibit the continued blebbing of 
plasma cell membrane, impaired pseudopod 
protrusion and cell motility. When FLNA 
deficiency has been restored in these cell 
lines by transfecting the full-length coding 
sequence of FLNA, cell migration has been 
normalized and they migrate five times faster 
than FLNA-deficient cells in response to a 
chemoattractant [105].  
In 2006, two different Flna-deficient mouse 
models were developed, one which is 
chemically induced and another which is a 
genetically modified model. A nonsense 
mutation has been introduced in Ig-repeat 22 
(Y2388X), designated as Dilp2 in the 
chemically induced model, and it results in 
the loss of Flna function [42]. This mutation 
is induced by N-ethyl-N-nitrosourea, which 
results in the conversion of tyrosine to stop 
codon, causing lethality in males due to 
arterial trunk, midline fusion defects and 
palate abnormalities in males [42]. A 
genetically modified mouse has in fact been 
generated by introducing flox sites in the 
Flna gene between introns 2 and 7 in female 
mice. The crossbreeding of these female mice 
with β-actin Cre male mice results in earlier 
truncation at the 121 amino acid in the CH1 
domain, causing embryonic lethality in 
males, with severe cardiovascular 
abnormalities and abnormal vascular 
patterning [18]. Surprisingly, none of these 
mouse models shows the PVNH phenotype, 
which might be due to a compensatory role 
for the Flnb isoform or else the mouse 
genome is not entirely similar to the human 
genome. 
In the following years, more Flna-deficient 
mouse lines have been developed to study 
distinct roles for Flna in specific cell types. 
Mice that are deficient in Flna, specifically in 
smooth-muscle cells, have lower blood 
pressure, along with a decreased pulse rate, 
aortic dilation and an increase in atrial 
compliance [106]. Mice that are deficient in 
Flna, specifically in megakaryocyte cells, 
have severe macrothrombocytopenia due to 
accelerated platelet clearance, accompanied 
by lethality in late embryogenesis. The Flna-
deficient megakaryocyte cells are 
prematurely large and have fragile platelets 
which are quickly cleared by macrophages in 
circulation [107]. Mice that are deficient in 
Flna, specifically in endothelial cells, show 
no abnormalities in vasculature or heart 
pump function, but, when myocardial 
infarction (MI) is induced in these mice, the 
endothelial cells in Flna-deficient mice fail to 
generate new blood vessels, which results in 
a larger infarction size. Nor do mice that are 
deficient in Flna in monocytes show any 
abnormalities. They are fertile and viable. 
However, Flna-deficient monocytes fail to 
develop multinucleated osteoclasts and poor 
monocyte migration, which might be 
controlled by Rho GTPase activation, 
indicating that Flna might be required in the 
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earlier stages of osteoclastogenesis [108]. In 
Study II, we deleted Flna in macrophages, 
similar to what is mentioned above, and we 
observed no phenotype in the mice, but, when 
atherosclerosis is induced as a result of a 
Western diet, mice deficient in FLNA in 
macrophages develop smaller plaques due to 
impaired macrophage cell migration, lipid 
uptake and cytokine response.  
Myocardial infarction 
MI is usually referred to as the death of the 
heart muscle, the myocardium. It is also 
usually referred to as a heart attack, but it is a 
different form, where the heart muscle is 
damaged due to reduced blood flow, resulting 
in cardiac arrest. This is an acute 
cardiovascular disorder caused by a short-
term or sudden change in blood flow to the 
heart. MI was responsible for more than 15 
million cases around the world in 2016 alone 
[109]. Smoking, diabetes, hypertension, 
reduced physical activity and obesity are 
some of the most important risk factors for 
MI. The symptoms include chest pain,
shortness of breath, a sensation of tightness
and radiating pain mostly in the left arm, but
it can also affect other parts of the body.
Other minor symptoms include sweating,
nausea and fainting; however, about 5% of
MI cases do not exhibit any of the symptoms.
Atherosclerosis is the main cause of MI due 
to the rupture of the plaque, blocking the 
artery and restricting blood circulation to the 
heart muscle [110]. The other factors which 
contribute to MI are limited oxygen demand 
or hypoxia conditions, hyperthyroidism and 
low blood pressure. The restriction or 
blockage of the artery near the heart muscle 
triggers an ischemic cascade where the heart 
cells in the surrounding tissue die due to 
necrosis and cannot be regenerated [111]. 
The surrounding tissue cells affected by 
oxygen obstruction have to generate ATP in 
mitochondria. This mechanism triggers 
necrosis and apoptosis in the affected cells 
[111]. The innermost tissue, the 
endocardium, is the most susceptible layer 
during damage, as ischemia is a first trigger 
here. The cells surrounding tissue begin to 
die within 15-30 minutes of obstruction and 
the first wave of muscle damage usually 
begins in three to four hours [111, 112]. The 
size and location of the infarct often 
determines the risk of heart abnormalities 
known as arrhythmias, aneurysms, 
inflammation in the heart wall and rupture 
[112]. 
An MI is mostly diagnosed by elevated levels 
of troponins which are usually released after 
four to eight hours and peak after one to two 
days of muscle damage [113]. A change in 
heart pump function and motion is detected 
by an echocardiogram, while thrombus 
formation is detected by an angiogram.   
Endothelial cells in myocardial 
infarction 
Endothelial cells are crucial for the formation 
of angiogenesis and vasculogenesis. The 
entire circulatory system from the heart to the 
smallest capillaries is covered in vascular 
endothelial cells. They are responsible for a 
wide range of functions, such as fluid 
filtration, blood vessel tone, hemostasis, 
neutrophil recruitment and hormone 
trafficking. The entire vascular system is 
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lined by a single layer of endothelial cells. 
The endothelium alone comprises of 1x1013 
cells in adults, almost equivalent to 1 kg of an 
organ [114]. The main function of endothelial 
cells is to maintain the structure and 
functional integrity of the vessel wall. They 
also act as a semi-permeable barrier 
regulating the transfer of small and large 
molecules [114]. When a person suffers an 
MI, the left ventricle undergoes dramatic 
changes at both the cellular and functional 
level of the heart [115]. Pro-angiogenic 
therapy has been long regarded as promising 
treatment, where vascular endothelial cells 
are induced to migrate to surround damaged 
heart tissue and promote angiogenesis to 
generate new blood vessels. Pro-angiogenic 
treatments have not been established, despite 
numerous efforts in hypoxia-induced 
angiogenesis. As a result, further detailed 
studies have to be performed on mechanisms 
dealing with vascular endothelial cells to 
prevent MI. FLNA has long been thought to 
be involved in cellular migration and 
angiogenesis and the loss of FLNA results in 
PVNH, accompanied by other cardiovascular 
phenotypes in humans. The loss of Flna 
function in the mouse is accompanied by 
embryonic lethality caused by severe cardiac 
malformations and abnormal vascular 
patterning [18]. So, in Study I, we studied the 
role of the vascular endothelial-specific 
expression of FLNA post MI by deleting 
Flna in endothelial cells. 
Atherosclerosis 
Atherosclerosis is a chronic inflammatory 
disease and it is involved in every stage of 
CVD [116, 117]. Atherosclerosis is generally 
classified by the build-up of plaque and the 
formation of fatty streaks in the arteries 
[118]. It is a major cause of death in the USA, 
Europe and a few parts of Asia. In Sweden, 
around one million people suffer from CVD 
and most of these cases are atherosclerosis 
related. The progression of atherosclerosis 
disease is based on two hypotheses; during its 
early phase, by the initial response of the 
inflammatory cascade to endothelial 
dysfunction, followed by the retention of 
low-density lipoproteins (LDL) in the wall of 
arteries [119], while the other hypothesis is 
that the lipids come first and are followed by 
endothelial injury, which is supported by the 
presence of fatty streaks in the absence of 
inflammation [120, 121]. Even though 
atherosclerosis has a high mortality rate, the 
progression of the disease is still debatable. 
However, the most widely accepted theory is 
systemic inflammation during the 
progression of atherosclerosis. Regardless of 
which hypothesis comes first, elevated levels 
of lipids are responsible for most of the 
disease progression, followed by 
hypertension, diabetes, oxidative stress and 
viral infections [122]. Atherosclerosis 
generally remains asymptomatic until the age 
of 40 or 50 years, after which it becomes a 
major cause of death in Western countries. 
So, a better understanding of disease 
progression may give us clues to how cell 
signaling and cytokine production are 
regulated. 
Macrophages in atherosclerosis 
Macrophages are generally phagocytic cells 
and execute immune properties as they 
engulf and digest all foreign materials in 
body [123] and play a vital role in 
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atherosclerosis. The macrophage is a white 
blood cell that exists in various tissues such 
as Kupffer cells, alveolar macrophages, 
microglia and osteoclasts. Nevertheless, its 
function remains same; the phagocytosis of 
different foreign or unwanted particles. 
Macrophages act as both inflammatory and 
anti-inflammatory cells by secreting a 
number of different cytokines and growth 
factors [123]. Along with foreign materials, 
macrophages also engulf fatty deposits and 
form foam cells in the blood vessel wall 
[124]. The formation of foam cells and 
thereby the build-up of plaque results in 
either the rupture of plaque or the narrowing 
of blood vessels, resulting in the blockage of 
the oxygen supply to the heart and other vital 
organs. This results in severe complications 
such as stroke and cardiac and renal failure 
[125]. Generally, atherosclerotic lesions 
comprise early and late lesions. Early lesions 
are usually clinically silent; the lesions start 
to grow from small deposits of intracellular 
lipids into extracellular lipid pools, whereas 
late lesions  grow from an extracellular lipid 
core to surface defects including ulceration, 
thrombosis, rupture and hemorrhage [125]. 
FLNA is involved in both cellular migration 
and the induction of the inflammatory 
cascade by interacting with multiple 
signaling molecules. In Study II, we 
hypothesized that a deficiency in FLNA in 
macrophages reduces macrophage migration, 
lipid uptake and cytokine release in vitro and 
reduces atherosclerotic plaque formation in 
mice.  
Human mutations in 
filamin A gene 
Due to the versatile function of FLNA in cell 
migration and cell signaling, mutations of 
FLNA cause a varying range of 
developmental malformations which are 
even associated with cardiovascular 
disorders, whereas FLNB and FLNC 
mutations are mainly restricted to skeletal 
and cardiac muscle dysfunction. Since these 
proteins are a recent entry in the research 
field, their more predominant functions are 
yet to be discovered. 
The first discovered mutation in the FLNA 
gene is the null mutation where coding amino 
acids are converted to a stop codon in exon 3, 
resulting in PVNH, where a six-layer 
neocortex is not formed due to failed 
neuronal migration [41]. PVNH is mainly 
linked to females, while the majority of 
hemizygous males are confined to embryonic 
lethality and liveborn males display aortic 
dilation and die from massive hemorrhage in 
the neonatal period [41]. Female patients 
with PVNH run a huge risk of strokes and are 
associated with other cardiovascular 
abnormalities like valvular abnormalities, 
persistent ductus arteriosus and aneurysms in 
the aorta [41]. A cluster of missense 
mutations resulting in substitutions of ABD 
have been identified, mainly in the Ig-repeats 
of 9, 10, 14, 16, 22 and 23 of FLNA [126]. 
These missense mutations are discovered in 
the otopalatodigital syndrome, Melnick-
Needles syndrome and front metaphyseal 
dysplasia [127]. They are also accompanied 
by cardiac, tracheobronchial and urological 
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malformations, resulting in perinatal death 
[127]. However, phenotypes caused by the 
otopalatodigital syndrome, Melnick-Needles 
syndrome and front metaphyseal dysplasia 
are very distinct from PVNH [128].  
The genomic deletion of codons for exon 19 
that results in X-linked myxoid valvular 
dystrophies (XVMD) in the heart, a specific 
cardiovascular malformation [129]. XVMD 
are frequently involved in anomalies of the 
vasculature, which includes mitral valve 
prolapse, as well as mitral and aortic 
regurgitation. It is known that a defective 
signaling cascade in TGF-β results in 
impaired mitral valve remodeling and FLNA 
contributes to changes in cardiac valves by 
regulating the TGF-β signaling cascade via 
interaction with SMADs [61]. XVMD are not 
linked with PVNH and other congenital 
disorders mentioned above. Exon 21 
nonsense mutations, frameshift and 4-shift 
mutations have been identified in FLNA to 
cause bilateral PVNH, along with Ehlers-
Danlos syndrome, accompanied by minor 
cardiovascular malformations [130]. A 
variant of PVNH associated with FLNA 
mutations and Ehlers-Danlos syndrome leads 
to the development of aortic dilation during 
early childhood [131]. 
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Aims  
Our previous studies indicated that FLNA regulates cell migration in both organ development and 
tumor progression. A deficiency of FLNA results in impaired oncogenic angiogenesis and tumor 
cell signaling. In this thesis, we determine the biological importance of FLNA in adaptive 
angiogenesis during cardiovascular remodeling. 
Specific aims 
We hypothesized that the absence of FLNA in endothelial cells impairs endothelial cell function 
and signaling and thereby worsens remodeling after myocardial infarction. 
We hypothesized that the absence of FLNA and the inhibition of FLNACT produced by calpain 
cleavage in macrophages impair cytokine secretion, lipid uptake and thereby reduce 
atherosclerotic plaque size. 
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Methods 
Histology and image analysis 
In Study I, mouse hearts were extracted after 
arresting them in a diastolic state following 
the injection of 30 mM KCl intracardially. 
They were then processed with standard 
histology for further analysis. The hearts 
were sectioned at five different levels, 1 mm 
between each level, starting from the apex, 
and stained for Mason’s trichrome to 
determine the infarction size between the 
groups. Images of the stained heart sections 
were captured using a Mirax scanner and the 
infarction size was quantified by Biopix 
software, as described earlier [31].  
In Study I, human infarcted hearts and mouse 
infarcted hearts were paraffin embedded and 
sectioned at 6 µm and stained for 
hematoxylin and eosin (H&E). In Study II, 
human carotid endarterectomies and mouse 
aortas were paraffin embedded and sectioned 
at 6 µm, starting 2 mm from the aortic arch, 
and stained for H&E, as described earlier 
[132]. 
In Study I, paraffin-embedded human 
infarcted and mouse infarcted hearts were 
sectioned at 6 µm and stained 
immunohistochemically with antibodies 
against FLNA (Chemicon International), 
FLNB (Chemicon international) and FLNC 
(Kinasource), as described earlier [133]. In 
infarcted and non-infarcted regions of mouse 
hearts, a number of endothelial positive 
capillaries and replicating cells were stained 
immunofluorescently with CD31 (Thermo 
Scientific) and Ki67 (Thermo Scientific) 
respectively, from at least seven mice in each 
group. Images were captured using a Leica 
Microsystems microscope. CD31-positive 
structures were counted manually and the 
Ki67 staining intensity was quantified using 
Biopix software, as described earlier [134]. 
In Study II, we stained advanced (type VI) 
and intermediate (type III) atherosclerotic 
plaques, obtained from a human carotid 
endarterectomy biobank provided by the 
Göteborg Atheroma Study Group (GASG), 
as characterized histopathologically earlier 
[135]. These paraffin-embedded sections 
were immunofluorescently stained using 
primary antibody CD68 recognizing 
macrophages (DAKO), FLNA (Bethyl 
Laboratories), smooth muscle-specific α-
actin (Sigma Aldrich) recognizing vascular 
smooth-muscle cells and CD31 (DAKO) 
recognizing endothelial cells. DAPI was 
included for nuclear staining. Appropriate 
Alexa anti-rabbit and Alexa anti-mouse 
(Jackson ImmunoResearch) were used as 
secondary antibodies, as described earlier 
[136]. 
Conditional gene knockout 
strategy 
All the mice used in these studies had a 
C57BL/6 background. In Study I, female 
mice expressing homozygously floxed sites 
flanked between exon 2–7 in the Flna gene 
(Flnafl/fl) were crossbred with male mice 
heterozygously expressing Cre under the 
control of vascular endothelial cell-specific 
cadherin promoter (VECadCre+) (Figure 2). 
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This type of Cre murine line is the model 
mostly common and widely used to target 
gene expression specifically in vascular 
endothelial cells [137]. In Study II, female 
mice expressing homozygously floxed sites 
of Flna (Flnafl/fl) were crossbred with male 
mice homozygously expressing Cre under the 
control of monocyte/macrophage-specific 
lysozyme-M promoter (LC). This type of Cre 
murine line is the model most commonly 
used to delete gene expression in 
macrophages [138]. Experimental mice were 
selected by PCR genotyping for the presence 
of the Flnao/fl allele and Cre (Figure 2), as 
described earlier [31].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cell-specific deletion of filamin A in mice. (A) Schematic illustration of the Cre-loxP system, 
where the floxed Flna gene is recognized by Cre recombinase, resulting in the deletion of Flna between 2–
7 exons. (B) Confirmation of the presence of flox sites and the deletion of the Flna gene by PCR analysis.
Cell culture 
Endothelial cells 
In Study I, mouse primary endothelial cells 
were isolated from both mouse heart and 
lung. The tissues were dissected into very 
fine pieces and passed through a cell strainer 
until a single cell suspension was achieved. 
The cell suspension was incubated with 
Dynabeads (M-450, sheep anti-rat IgG, 
Invitrogen) coated with rat anti-ICAM2 (BD 
Biosciences). The endothelial cell-bound 
beads were washed with RPMI medium, 
along with growth factors, and plated on 
collagen II-coated culture dishes, as 
described earlier [31]. 
To study the expression of signaling 
molecules after silencing for FLNA, 
transformed mouse pancreatic endothelial 
MS1 (ATCC) was cultured in normal DMEM 
growth medium in Study I, as described 
earlier [133]. To study the tube formation 
assay, human umbilical vein endothelial cells 
(HUVEC) were cultured in basal medium 
supplemented with growth factors (EBM-2 
bullet kit LONZA), as described earlier 
[134]. 
Macrophages 
Primary macrophages were isolated from 
bone marrow of either control or 
experimental mice. Murine bone marrow was 
collected from the tibia and femurs and lysed 
using red blood cell lysis. Lysed bone 
marrow was then re-suspended in RPMI 
medium, along with mouse cardiomyocyte 
growth medium (CMG) as a source of M-
CSF supernatant. To transform monocytes 
into macrophages, 10–15 million cells were 
plated on 15 cm plates and cultured for at 
least seven days, along with CMG.  
Human primary macrophages were isolated 
from peripheral donor blood and cultured 
with M-CSF for five days before 
experiments, as described earlier [139]. 
Human THP1 cells were supplemented with 
100 nm of PMA to transform cultured 
monocytes into macrophages, as described 
earlier [132]. 
Cells assays 
Migration  
Wild-type (wt)- and Flna-deficient 
endothelial cells (Study I) and macrophages 
(Study II) were seeded in 8 µm Boyden 
chamber inserts and cultured for 8-12 hours. 
Migrated cells were fixed and stained and the 
number of migrated cells was counted, as 
described earlier [31]. 
Proliferation 
In Study II, wt- and Flna-deficient 
macrophages were seeded in six-well plates 
and cultured for up to five days. The total 
number of cells was counted every day and 
the average number of proliferated cells was 
plotted between the groups. 
Cell shape assay 
To determine the morphology of the cells, we 
stained wt-, Flna-deficient and MS1 
endothelial cells for actin filaments (Study I) 
and mouse primary macrophages (Study II) 
with Alexa flour Phalloidin 488 (Life 
Technologies) and the nucleus with DAPI, as 
described earlier [140]. Images were 
captured using a Zeiss microscope. 
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Tube formation assay 
In Study I, HUVEC cells transfected with 
scrambled control or FLNA siRNA were 
assayed on Matrigel-coated chamber slides 
overnight. The images were captured using a 
Zeiss microscope and the total number of 
formed tubes and the individual length of 
each tube formed between the groups were 
quantified using Image J software, as 
described earlier [140]. 
Foam cell formation and cholesterol efflux 
assay 
In Study II, wt- and Flna-deficient and 
FLNA-silenced mouse and human primary 
macrophages were incubated with 50 μg/mL 
of minimally oxidized LDL (mmLDL, Kalen 
Biomedical) to measure the intracellularly 
accumulated level of mmLDL within 24 
hours. Macrophages were then stained with 
an Oil-red-O stain and the nucleus was 
stained with hematoxylin to determine the 
accumulated lipids. Four random images 
were captured from each well using Leica 
Microsystems and the total accumulated 
lipids were quantified using Biopix software. 
For lipid uptake assay, wt- and Flna-deficient 
macrophages were incubated with 
fluorescently labeled, either Dil-labeled total 
LDL or OxLDL (Invitrogen), for three hours. 
Four random images were captured from 
each well using Leica Microsystems and 
fluorescence intensity was analyzed using 
Biopix software, as described earlier [132]. 
To study the levels of excreted cholesterol,  
5 x 105 wt- or Flna-deficient macrophages 
were seeded in 24-well plates and incubated 
with 50 μg/mL of acetylated LDL (AcLDL) 
and 5 μCi/mL of 3H-labeled cholesterol 
(Perkin Elmer) for 24 hours. These 
macrophages were rested overnight and 
treated separately with 20 μg/mL of HDL 
(Calbiochem) or 20 μg/mL of ApoAI (Sigma 
Aldrich) as the cholesterol acceptor for 12 
hours. The levels of excreted 3H-labeled 
cholesterol in the cell culture medium were 
then measured using a scintillation counter. 
The results were normalized to protein 
concentration, as described earlier [132].  
Silencing mRNA expression of filamin A 
MS1, HUVEC cells (Study I), human 
primary macrophages and THP1 (Study II) 
were transfected with control siRNA or 
siRNA FLNA (5′-
TACAGGCAATATGGTGAAGAA-3′) and 
shRNA control or shRNA FLNA 
(5′GGAGTGCTATGTCACAGAAAT-3), 
according to the manufacturer’s protocol 
(Life Technologies). The efficiency of FLNA 
silencing was confirmed by either 
immunoblotting or real-time PCR. 
Real-time PCR 
Total mRNA was synthesized from both wt- 
and FLNA-deficient endothelial cells, 
HUVEC and MS1 cells (Study I) and human 
primary macrophages and THP1 cells (Study 
II). Total mRNA was synthesized to cDNA 
(Quanta Biosciences kit). The efficiency of 
FLNA silencing was measured by 
(Mm01187533-m1) probes and normalized 
to GAPDH.  
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Immunoblotting 
Proteins were isolated from wt- and Flna-
deficient endothelial cells (Study I) and 
macrophages (Study II). Proteins were 
isolated using mammalian cell lytic buffer 
(Sigma Aldrich) and the protein 
concentration was measured using a BCA 
assay (Pierce). Primary antibodies directed 
against FLNA (Chemicon, Bethyl 
Laboratories and Novus Biologicals), p-
STAT3 (Cell Signaling), total STAT3 (Cell 
Signaling), p-AKT, total AKT, p-ERK1/2, 
total ERK1/2 (Cell Signaling), SR-B1 (Santa 
Cruz Biotechnology), LXRα/β, CD36, 
COX2, ABCG1 and ABCA1 (Novus 
Biologicals) were used. The protein 
expression between the groups was analyzed 
by their densitometric readings using 
Quantity One 4.4 software (Bio-Rad) in at 
least quadruplicates, as described earlier 
[140]. Cells were stressed with either serum 
starvation overnight (Study I) or treated with 
10 ng/ml lipopolysaccharide (LPS) for 15 
minutes (Study II) before the isolation of 
proteins.  
Nuclear and cytosolic protein extracts were 
separated using an extraction kit (Thermo 
Scientific) to study p-STAT3 in Study II. 
Tubulin served as a cytoplasmic loading 
control and histone served as a nuclear 
protein loading control. 
For the co-immunoprecipitation assay, total 
cell lysates were immunoprecipitated using 
antibodies against either FLNACT or STAT3. 
Dynabeads were coupled with targeted 
antibody and antibody-bound beads were 
incubated with at least 1 mg of total protein 
overnight. These beads were washed and then 
immunoblotted for either FLNACT or 
STAT3, according to the manufacturer’s 
protocol (Thermo Scientific). 
ELISA 
In Study I, secreted levels of N-terminal 
prohormone of brain natriuretic peptide (NT-
proBNP) (Bio Source) and VEGF-A (R&D 
Biosystems) were studied from mouse serum. 
In Study II, interleukins IL-6, IL-10 and IL-
12 were detected from either mouse serum or 
cultured macrophage medium, as described 
earlier (eBiosciences). In Study II, 
macrophages were cultured in 96-well plates, 
along with LPS (10 ng/ml), for eight hours 
with or without the calpain inhibitor, 
calpeptin (80 μM) or STAT3 inhibitor DPP 
5,15 (60 μM), and secreted cytokine levels 
were then detected from cultured medium, as 
described earlier [132]. 
Mouse model of myocardial 
infarction  
As previously reported [134], 14 to 16-week-
old control (Flnao/fl) and experimental mice 
that are deficient in Flna in endothelial cells 
(Flnao/fl/VECadCre+) were used for 
myocardial infarction (MI) surgery. The left 
anterior descending artery (LAD) was 
permanently ligated to induce MI. During the 
surgical procedure, the mice constantly 
inhaled 3% isoflurane and 30% oxygen. 
Buprenorphine at a concentration of 0.05% as 
an analgesic agent was administered 
intraperitoneally after surgery. An ultrasound 
was performed a week later to determine the 
size and location of ligation. After 25 weeks, 
a cardiac ultrasound was performed under 
2% isoflurane to record cardiac parameters 
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such as echocardiography, the ejection 
fraction and lumen areas between the groups. 
For a stress test, dobutamine was 
administered intraperitoneally (1µg/g mouse 
body weight). An ultrasound was performed 
after the administration of dobutamine at 
baseline, five and 15 minutes to study 
whether cardiac parameters were altered 
between the groups. The hearts were 
extracted after arresting them in a diastolic 
state following an intracardial injection of 30 
mM of KCl and subsequently processed with 
histology for further analysis, as mentioned 
above.  
Mouse model of atherosclerosis  
Bone marrow transplantation 
In Study II, 12-week-old Ldlr–/– mice were 
irradiated by a lethal 9.5 Gy dose, as 
previously described [141]. Bone marrows 
were isolated from 10-12 weeks of age from 
either control mice (Flnao/fl) or mice 
deficient in Flna in macrophages 
(Flnao/fl/LC). Bone marrow was suspended 
in RPMI1640 without phenol red and two to 
four million cells per mouse were injected 
intravenously via the tail vein into Ldlr–/– 
mice four hours after irradiation. A week 
after transplantation, these mice were fed a 
Western (high fat, high cholesterol) diet 
containing 1.25% cholesterol until 25 weeks. 
Adenoviral infection of PCSK9 vector 
In Study II, we induced atherosclerosis by 
infecting Flnao/fl and Flnao/fl/LC mice with 
2x1011 particles of adenoviral vector (Ad) 
overexpressing proprotein convertase 
subtilisin/kexin type 9 (PCSK9) injected 
intravenously, as described earlier [142]. 
These mice were fed a Western diet 
containing 1.25% cholesterol until 25 weeks. 
In vivo calpeptin treatment 
Following the induction of atherosclerosis by 
AdPCSK9, 8 to 10-week-old C57BL/6 mice 
were treated with or without calpeptin and 
then fed a Western diet for 20 weeks. The 
control mice were injected with DMSO 
dissolved in saline. Treatment with calpeptin 
was administered at a dose of 0.65 mg/kg 
dissolved in saline. DMSO and calpeptin 
were injected intraperitoneally three times 
weekly during the last eight weeks. After 20 
weeks, aortas were isolated and stained with 
Sudan IV, as described below. 
After 20-25 weeks of a Western diet, entire 
mouse aortas were isolated from the aortic 
arch to the iliac bifurcation. Aortas were 
fixed with 4% formaldehyde, pinned out 
under an inverted microscope and stained 
with Sudan IV. Stained aorta images were 
captured by an inverted Leica microscope 
and then analyzed by using Biopix software. 
Statistics 
All the graphs were plotted using GraphPad 
Prism 6 and either a two-tailed Student’s t test 
or one-way ANOVA statistical analyses were 
performed between the experimental groups. 
All results were reported as means ± SEM 
values. A P value of less than 0.05 was 
considered significant. Regarding the 
analysis of the intensity of co-localized 
FLNA expression in macrophages present in 
intermediate and advanced plaques of human 
carotid endarterectomies, a test of Mander’s 
overlap coefficients was applied.
Summary of results 
Study I: Deficiency of filamin A in endothelial cells impairs left ventricular 
remodeling after myocardial infarction. 
Recently, an increasing number of 
discoveries have shown that human FLNA 
mutations or a loss of function are associated 
with various cardiovascular abnormalities, 
such as valvular dystrophy, aortic dilation, 
patent duct arteriosus and cardiac valve 
disease [5]. This has prompted us to study the 
biological role of FLNA in endothelial cells, 
as these cells cover the inside of vessels and 
are involved in angiogenesis. Mice that are 
deficient in Flna in endothelial cells did not 
exhibit any differences in cardiac function 
parameters and no abnormality was observed 
in vascular patterning. However, tumors 
inoculated in these mice developed a smaller 
size compared with controls, probably due to 
poor endothelial cell function. These findings 
encouraged us to determine the role of the 
endothelial cell-specific expression of FLNA 
during the development and progression of 
MI, as the demand for endothelial response 
and signaling is very high. 
We observed that mice that are deficient in 
Flna in endothelial cells displayed an 
enlargement and thinning of the left ventricle 
wall, due to increased infarction size and 
impaired cardiac function following MI. 
Mice that are deficient in Flna in endothelial 
cells exhibited a larger infarction size (Figure 
3A), impaired cardiac pump function (Figure 
3B) and reduced capillarity, along with 
decreased left ventricle thickness (Figure 3C) 
and elevated NT-proBNP levels (Figure 3D). 
In the absence of FLNA in endothelial cells, 
we observed impaired tube formation, 
migration and signaling in endothelial cells. 
These results indicated that FLNA plays an 
important role in endothelial cell function 
and signaling, as a deficiency in FLNA in 
endothelial cells resulted in an increase in MI 
size and the development of cardiac failure. 
These new roles of FLNA provide new 
insights into the mechanisms behind cardiac 
remodeling and thus contribute to the 
development of new strategies to improve 
heart function after MI. In conclusion, the 
deletion of Flna in endothelial cells increases 
MI size, with attenuated cardiac parameters, 
due to a poor angiogenic response that is 
required for wound healing.  
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Figure 3. Increased size of MI and reduced cardiac function in hearts deficient in FLNA in 
endothelial cells. (A) Histomorphological changes in control hearts (Flnao/fl) and hearts that are deficient 
in FLNA in endothelial cells (Flnao/fl/VECadCre+) 25 weeks post MI, as detected by Masson’s trichrome 
staining. Blue color represents the infarcted area, whereas red represents healthy non-infarcted myocardium 
(left panel). Image quantification of infarcted scar size (right panel). (B) Percentage of estimated ejection 
fraction between Flnao/fl and Flnao/fl/VECadCre+. (C) Measurement of histomorphological changes in 
left ventricular thickness. (D) Secreted serum levels of NT-proBNP, a biochemical marker of cardiac 
failure, 25 weeks post MI. 
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Study II: Targeting filamin A reduces macrophage function and 
atherosclerotic plaques in mice. 
Atherosclerosis is a chronic disease with no 
cure to date. Understanding the molecular 
mechanisms in atherosclerotic disease 
progression will open doors to future curative 
treatment modalities. Macrophages play a 
key role in the progression of atherosclerotic 
plaques by taking up circulating lipids, 
forming foam cells and secreting 
inflammatory cytokines. FLNA regulates cell 
migration and proliferation in multiple cell 
types such as vascular endothelial cells and 
fibroblasts [31]. In this study, we 
hypothesized that macrophages that are 
deficient in Flna were able to migrate and 
proliferate less and this might then slow 
disease progression. To study this hypothesis, 
we deleted Flna in mice, specifically in mice 
macrophages, and induced atherosclerosis 
either by transplanting bone marrow that is 
deficient in FLNA in macrophages into 
atherogenic mice or by the overexpression of 
AdPCSK9 using an adenoviral vector and 
subjected mice to a Western diet for 20-25 
weeks. 
Macrophages without filamin A proliferate, 
migrate and secrete less IL-6 
To determine whether FLNA has any effect 
on cell migration and/or lipid uptake in 
macrophages, we studied cell function by 
extracting primary macrophages from mouse 
bone marrow. Flna deficiency in these 
macrophages (Flnao/fl/LC) resulted in 
impaired proliferation starting on day 4 
(Figure 4A) and macrophage cell migration 
after eight hours (Figure 4B), as compared 
with wt-control macrophages (Flnao/fl). 
Subsequently, we studied atherogenesis in 
vivo by transplanting bone marrow from 
either control (Ldlr–/– BMT: Flnao/fl) or Flna-
deficient mice (Ldlr–/– BMT: Flnao/fl/LC) into 
atherogenic Ldlr–/–-deficient mice. These 
mice were subjected to a Western diet and 
their aortas were isolated after 25 weeks. The 
aortas were fixed, pinned and stained with 
Sudan IV to quantify fat plaques. Whole 
images of Sudan IV-stained aortas were 
captured and quantified using Biopix 9.2 
image analysis software. We observed that 
atherogenic mice that received bone marrow 
deficient in FLNA in macrophages (Ldlr–/–
BMT: Flnao/fl/LC) developed significantly 
(55%) less plaque compared with controls 
(Ldlr–/– BMT: Flnao/fl) (n = 11 and 13, 
respectively) (Figure 4C). To explain this 
decrease in atherosclerotic plaque size, we 
discovered that STAT3 interacts physically 
with FLNACT (Figure 4D). Nuclear levels of 
p-STAT3 were significantly reduced in
Flnao/fl/LC compared with Flnao/fl
macrophages. Furthermore, blocking the
production of FLNACT by calpeptin
significantly reduced nuclear p-STAT3 to
levels similar to those of Flnao/fl/LC
macrophages (Figure 4E). Decreased levels
of nuclear p-STAT3 reduced the secretion of
inflammatory cytokine IL-6 in both
Flnao/fl/LC macrophages treated with
calpeptin as compared to Flnao/fl (Figure 4E)
macrophages, suggesting that FLNACT plays
an important role in regulating IL-6 secretion
by interacting with STAT3.
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Figure 4. Impaired macrophage cell function and signaling in the absence of FLNA. (A) 
Number of proliferating Flnao/fl and Flnao/fl/LC macrophages up to five days. (B) Number of migrated 
Flnao/fl and Flnao/fl/LC macrophages after eight hours. (C) Images from Sudan IV-stained aortas obtained 
from Ldlr–/– mice receiving either Flnao/fl or Flnao/fl/LC bone marrow (right panel). Percentage of plaque 
areas as quantified by image analysis of Ldlr–/– BMT: Flnao/fl or Ldlr–/– BMT: Flnao/fl/LC aortas (left panel). 
(D) Co-immunoprecipitation between FLNACT and STAT3 indicates that STAT3 is an interacting partner
of FLNACT. (E) Quantification of nuclear levels of p-STAT3Y705 between Flnao/fl, Flnao/fl/LC and
calpeptin-treated macrophages. (F) Secreted levels of IL-6 between Flnao/fl, Flnao/fl/LC and calpeptin-
treated macrophages as detected by ELISA.
Filamin A-deficient macrophages take up 
lipids poorly 
We then investigated whether Flna 
deficiency has any effect on foam cell 
formation and the uptake of lipids in 
macrophages, possibly explaining the lower 
plaque in Ldlr–/– BMT: Flnao/fl/LC aortas. 
Flnao/fl/LC macrophages formed a 
significantly reduced number of foam cells. 
Similarly, we observed reduced foam cell 
formation in calpeptin-treated macrophages, 
as well as the specific inhibition of STAT3 
signaling by 5,15 DPP-treated macrophages 
compared with control Flnao/fl macrophages 
(Figure 5A). Oxidized lipids were also taken 
up poorly in both Flnao/fl/LC and calpeptin-
treated macrophages as compared with 
control Flnao/fl macrophages (Figure 5B). 
We further investigated whether blocking the 
production of FLNACT alters macrophage 
cell proliferation and migration after 
treatment with calpeptin. This treatment 
completely inhibited macrophage 
proliferation (Figure 5C) and partly blocked 
macrophage migration in vitro (Figure 5D).  
Calpeptin treatment reduces plaque 
formation in mice 
Based on our in-vitro results from calpeptin 
treatment, we initiated studies to determine 
whether calpeptin was able to inhibit 
atherogenesis in vivo. To achieve this, we 
induced atherosclerosis in eight- to 10-week-
old C57BL/6 mice by infection with 
AdPCSK9. These mice were fed a Western 
diet for 20 weeks and treated with calpeptin 
at a dose of 0.65 mg/kg three times a week 
intraperitoneally for the last eight weeks. 
Aortas were pinned and stained for the 
presence of fatty plaques and these plaques 
were quantified as described above. We 
observed that calpeptin-treated aortas 
displayed areas of plaque that were 
significantly reduced by 49% as compared 
with control aortas (Figure 5E). 
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Figure 5. Treatment with calpeptin impairs macrophage function and reduces the size of 
atherosclerotic plaques. (A) Quantification of total accumulated minimally modified lipids in 
macrophages between the Flnao/fl, Flnao/fl/LC, calpeptin and a STAT3 inhibitor 5,15 DPP treatment 
groups after 24 hours. (B) Quantification of oxidized lipid uptake in macrophages between Flnao/fl, 
Flnao/fl/LC and calpeptin treatment groups after three hours. (C) Fold changes in the number of 
proliferating macrophages between groups treated with or without calpeptin up to five days. (D) Number 
of migrated macrophages between groups treated with or without calpeptin after eight hours. (E). Images 
from Sudan IV-stained aortas obtained from C57BL/6 mice infected with AdPCSK9, treated with or 
without calpeptin (right panel). Percentages of plaque area quantification by image analysis (left panel).  
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Discussion 
Recent data indicate that, in addition to its 
cytoskeletal function, FLNA performs 
multiple functions in cellular signaling and 
transcription. In the studies in this thesis, we 
reported novel functions of FLNA during 
cardiovascular remodeling after MI and 
atherosclerosis. In the absence of FLNA in 
endothelial cells, the infarction size after MI 
was increased, probably due to impaired 
endothelial cell function and signaling. In the 
absence of FLNA in macrophages, the size of 
atherosclerotic plaques was reduced due to 
impaired macrophage function and signaling. 
To understand these biological roles of 
FLNA, we cultured both murine and human 
cells assayed for multiple functions in the 
absence or presence of FLNA in vitro. We 
then produced mice lacking FLNA in specific 
vascular cells to study cardiovascular 
remodeling. 
An increased infarction size can be explained 
by three major factors. First, the absence of 
FLNA in endothelial cells resulted in 
impaired LV remodeling accompanied by 
increased infarction size and a thinned and 
enlarged LV wall after MI. Second, a reduced 
number of capillaries were observed in the 
peri-infarcted areas. Third, endothelial cells 
deficient in Flna displayed impaired cellular 
signaling, resulting in reduced migration and 
tube formation. Cardiac parameters were not 
altered in response to dobutamine stress in 
mice deficient in Flna in endothelial cells. 
Furthermore, the serum levels of NT-proBNP 
were higher in these mice, indicating an 
increased ventricular response to volume 
expansion and possibly increased wall stress 
as a marker of heart failure.  
The innermost layer of heart chambers is 
called the endocardium and it is covered by 
endothelial cells. The regenerating capability 
of cardiomyocytes is very limited and 
advanced atherosclerotic plaques reduce 
blood circulation in areas with 
cardiomyocytes requiring nutrients. To 
support cardiomyocytes in MI, endothelial 
cells are essential in the formation of new 
vessels by active migration and proliferation. 
Interestingly, we only observed a reduced 
number of capillary structures in infarcted 
areas. However, the number of capillary 
structures in non-infarcted areas remained 
unchanged. This suggests that angiogenesis 
regulated by FLNA was induced when these 
mice were exposed to a stressed condition. In 
the absence of stress, these mice did not 
exhibit any phenotype. We have shown no 
difference in endothelial cell proliferation, in 
contrast to fibroblasts and multiple cancer 
cell lines, in which the absence of FLNA 
reduces cellular proliferation. However, 
impaired endothelial cell migration in vitro in 
Flna deficiency may explain the increased 
size of MI in these mice. VEGF-A plays a 
dominant role in regulating angiogenesis 
during MI [143]. VEGF-A binds to VEGF 
receptor 2 to regulate downstream signaling 
molecules, including AKT, ERK and RAC-1 
GTPase, during angiogenesis [144]. From 
our previous findings, we report that 
FLNACT interacts with HIF-1α and regulates 
VEGF-A under hypoxia in human multiple 
cancer cells [72]. Interestingly, serum levels 
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of VEGF-A were decreased in mice deficient 
in Flna in endothelial cells after MI. The 
phosphorylation of kinases such as AKT and 
ERK1/2 and the level of active GTPase 
RAC1 were also reduced in cultured 
endothelial cells in the absence of FLNA 
(Figure 6). It is known that FLNA induces 
cellular migration either by direct interaction 
with RAC1 [108] or by the indirect regulation 
of VEGF-A [72]. In our studies, the absence 
of FLNA in endothelial cells increases the 
size of LV, decreases cardiac pump function 
and leads to the development of cardiac 
failure by blunting angiogenic responses that 
are required for satisfactory wound healing. 
Inducing cellular signaling pathways 
regulated by FLNA and related to 
angiogenesis during MI could be a new 
approach to reduce the size of an MI.  
Figure 6. Schematic illustration of a proposed role for FLNA in endothelial cells. The 
expression of ERK1/2 and AKT and RAC1 activation are induced by FLNA during endothelial cell 
migration and tube formation. 
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In the progression of atherosclerosis, 
macrophage proliferation, migration, foam 
cell formation and an inflammatory response 
are the main events [145]. In our study, we 
have shown that the size of atherosclerotic 
plaques in atherogenic Ldlr–/– mice receiving 
BMT deficient in Flna in macrophages was 
reduced. In addition, mice deficient in Flna 
in macrophages after overexpressing PCSK9 
by an adenoviral vector displayed 
atherosclerotic plaques with a reduced size. 
We hypothesized that this plaque reduction 
could be based on three major findings. First, 
Flna-deficient macrophages secrete lower 
levels of the pro-inflammatory cytokines, IL-
6 and IL-12, which could be partly regulated 
by STAT3 (Figure 7). Second, Flna-deficient 
macrophages proliferate and migrate less. 
Third, Flna-deficient macrophages take up 
fewer lipids and excrete more cholesterol as 
compared with wt-macrophage controls. 
Together, these three factors could explain 
the reduced size of atherosclerotic plaque in 
atherogenic mice deficient in Flna in 
macrophages. Cell migration and 
proliferation are regarded as key aspects in 
the progression of numerous diseases. We 
observed a smaller number of macrophages 
in the plaques in mice deficient in Flna in 
macrophages. In vitro, macrophages without 
FLNA proliferated and migrated less. This 
could be partly due to lower p-AKT and p-
ERK1/2 in the regulation of macrophage 
proliferation and migration, similar to the 
endothelial cells in Study I, as well as human 
melanoma cells [72].  
In atherosclerosis, macrophages secrete 
inflammatory cytokines in response to 
external stimuli. Anti-inflammatory therapies 
have long been thought to reduce 
atherosclerosis and the treatment of 
atherogenic Ldlr–/– mice with antibodies 
against the IL-6 receptor reduced the size of 
atherosclerotic plaques [146]. We observed a 
reduction in the secretion of IL-6 and IL-12 
in Flna-deficient macrophage cells, as well as 
in mice deficient in Flna in macrophages. It 
is known that STAT3 partly regulates IL-6 
secretion by binding to its promoter region 
[147]. In our in-vitro studies, we discovered 
that the FLNACT produced by calpain 
cleavage interacts with STAT3 and this 
complex is translocated into the nucleus to 
regulate the expression of IL6. We next 
determined that a deficiency of Flna in 
macrophages inhibits the nuclear p-STAT3, 
as well as IL-6 secretion in vitro. 
Interestingly, blocking FLNACT production 
by calpeptin treatment reduced the levels of 
nuclear p-STAT3, followed by the secretion 
of IL-6 in wt-macrophage controls to levels 
similar to those detected in Flna-deficient 
macrophages. This suggests that the cleavage 
of FLNA by calpain is important for STAT3 
signaling by increasing the nuclear levels of 
p-STAT3 and thereby increasing the
inflammatory response by IL-6 in
macrophages.
Lipid uptake and the excretion of lipids from 
macrophages are the main vascular events in 
the formation of atherosclerotic plaques. In 
our in vitro studies, we observed that Flna-
deficient macrophages take up fewer lipids 
and excrete more cholesterol. To explain 
these functional changes, we studied 
molecules that are involved in the unloading 
of cholesterol from macrophages without 
FLNA and discovered higher expression 
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levels of CD36, SR-B1 and COX2 by 
immunoblotting. Similarly, the treatment of 
control macrophages with calpeptin reduced 
foam cell formation as well as lipid uptake. 
Furthermore, the systemic administration of 
calpeptin reduced the size of atherosclerotic 
plaques in atherosclerotic control mice to 
levels similar to those we observed in mice 
deficient in Flna in macrophages in vivo.   
To summarize, either a deficiency of Flna in 
macrophages or blocking production of 
FLNACT by calpeptin reduced proliferation, 
migration, secretion of inflammatory 
cytokines and the formation of foam cells in 
vitro. These inhibitory effects may partly 
explain the reduced size of atherosclerotic 
plaques in vivo. In this study, we discovered 
a causal link for FLNA-dependent 
macrophage cell function during 
atherogenesis. Targeting the cleavage of 
FLNA by calpains might be a potential 
strategy to reduce plaque formation in 
atherosclerosis by decreasing macrophage 
proliferation and migration, the secretion of 
inflammatory interleukins and foam cell 
formation.  
Figure 7. Schematic illustration of proposed mechanism between FLNA and STAT3 in 
macrophages. Cleaved C-terminal fragment of FLNA by calpain (FLNACT) interacts with STAT3 and 
this interacting complex is then translocated into the nucleus to regulate IL6 gene expression.
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Future directions 
Filamin A as a prognostic marker 
We identified FLNA as an important protein 
involved in atherogenesis. In order to suggest 
that FLNA has the potential to be used as a 
prognostic biomarker, the detailed expression 
of FLNACT needs to be detected in carotid 
endarterectomies. If the expression of 
FLNACT is increased, these patients may risk 
the development of severe clinical 
complications, such as new brain infarction 
events. Using cationic liposomes during 
percutaneous transluminal coronary 
angioplasty, FLNA may be overexpressed in 
coronary endothelial cells to promote 
angiogenesis in patients with MI.   
FLNA is important during developmental 
stages and plays vital roles during 
embryogenesis, as a deficiency in FLNA is 
associated with lethality due to various 
severe malformations affecting the 
development of the heart, skeleton and brain 
in humans. Similarly, mice that are deficient 
in Flna die in utero due to severe 
cardiovascular malformations. Screening the 
presence and nature of FLNA mutations in 
humans and identifying the partner of FLNA 
that abolishes its binding capability in 
different mutated areas would be interesting 
in order to understand the biology behind the 
serious cardiovascular malformations. If 
critical FLNA mutations are identified, 
patients can be informed that they run a 
higher risk of developing cardiovascular 
malformations and can therefore be closely 
followed up by routine biochemical and 
radiological examinations. 
Calpain inhibitors to treat 
atherosclerosis 
Calpain inhibitors are widely used in various 
diseases, as mentioned above, but they have 
not been studied in detail in cardiovascular 
cells and disease remodeling. Calpain 
inhibitors have the potential to block the 
phosphorylation of FAK1, Src, Cdk5 and 
MAPK kinases that are involved in 
angiogenesis. In this thesis, we discovered a 
novel interaction by FLNACT with STAT3 in 
regulating the inflammatory signaling 
cascade that contributes to atherosclerotic 
plaque development. Blocking the 
production of FLNACT by calpeptin 
treatment impaired macrophage cell 
proliferation, migration, lipid uptake and 
nuclear p-STAT3 in vitro, as well as 
atherosclerotic plaque size in vivo. The 
systemic injection of calpeptin in mice did 
not produce any adverse effect on 
cardiovascular or liver histomorphology and 
ALT production. These results indicate that 
the inhibition of calpain might serve as a 
potential target to treat or at least slow 
atherogenesis. 
Future experiments 
As we discovered that the cleavage of FLNA 
by calpains is important for the nuclear 
presence of HIF-1α and STAT3, we plan to 
mutate predicted sites of the H1 region 
cleaved by calpain and then generate the non-
cleavable form of FLNA using a knock-in 
strategy using the CRISPR/Cas9 system in 
mice. Embryos expressing non-cleavable 
FLNA will be characterized for organ 
48 
development. If mice are born and survive 
normally, MI and atherosclerosis, as well as 
the growth of inoculated tumors, will be 
investigated using models that we have 
already established in our laboratory. 
49 
Acknowledgements 
This PhD thesis was mainly carried out at the Institute of 
Biomedicine, Department of Medical Biochemistry and Cell 
Biology, University of Gothenburg, Sahlgrenska Academy, 
between July 2014 and November 2018.  
First and foremost, I would like to express my sincere 
gratitude to my supervisor, Levent Akyürek, for accepting 
me as a PhD fellow, for your continuous support during my 
PhD studies and research, for your motivation, enthusiasm 
and immense knowledge. Your patience and contribution 
in developing me as a scientist is irreplaceable and without 
you I cannot imagine where I would be as a person. Thanks 
for enormously stimulating discussions not only in science 
but also in life and career and always letting me choose the 
right path. Your guidance has helped me throughout my 
research and the completion of this thesis. I could not 
imagine having a better mentor than you during my PhD. 
Previous and present members at the Laboratory of 
Akyürek. I would like to thank Alex-Xianghua Zhou, for all 
his help, support and guidance in almost everything during 
my initial stages. Without your guidance, I would have not 
been in this place. Thanks to Chandu Ala, my exceptional 
master’s student, for his help on my projects. Rajesh Kumar 
Nallapalli, for his initial support and brotherly love when I 
moved to Gothenburg. Thank you all for sharing your 
friendship, knowledge and happy occasions we enjoyed 
together. I would like to thank Reza Salami, Sravani 
Devarakonda, Sevtap Gökalp, Çağlar Çil and Ali Alvandian, 
who have supported me and created a friendly, enthusiastic 
atmosphere in the lab.  
I would like to thank my co-supervisor, Martin O Bergö, for 
the collaborative work and fruitful discussions. Thanks for 
letting me use the instruments and reagents at the 
Sahlgrenska Cancer Center whenever needed. Special 
thanks to Murali Krishna Akula, for helping me with many 
experiments and personally as well. Thanks for the friendly 
attitude and making me feel at home in Gothenburg. I 
would like to thank Christin Karlsson for her help with the 
Mirax scanner and irradiation system for bone marrow 
transplantation.  
I would like to thank Jan Borén, for extremely stimulating 
collaboration, for opening your group to me, for all the 
resources you allowed me to use at the Wallenberg 
Laboratory. I would like to thank Liliana Håversen, for all 
the exciting discussions and advices on lipid biology. I 
would like to thank Kristina Skålen, for animal experiments,
Elin Stenfeldt  for lipid fractionation analysis, Max Levin 
and Matias Ekstrand, for the immunofluorescence 
stainings in the atherosclerosis project, Samad Parhizkar 
50 
and Shahin de Lara, for the histological analysis of mouse 
aortas at the Department of Clinical Pathology, Erik 
Larsson and Joakim Karlsson, for the bioinformatics 
analysis, Elmir Ömerovic and Björn Redfors, for performing 
MI in mice, Julia Grönros, for the UCG examinations, Josefin 
Kjelldahl and Göran Bergström, for providing human 
endarterectomy samples and Abdulhussain Haamid, for all 
the help at the Laboratory of Experimental Biomedicine, 
and Jennifer Uhler, for linguistic help. 
I would like to thank my friends, especially Mikael Ahlgren, 
Marodana Glogov, Mattias Faltsetas and Zulfi Syed, for all 
the fun we had on fishing trips. My childhood friends Ankal 
Reddy and Sundeep Talluri and friends Vijay Kumar and 
Pradeep kopparapu , Chilaka venkatesh and Juttu Srinivas  
who always motivated me. 
These studies were mainly supported by the generous 
grants from the Swedish Cancer Foundation and ALF grants 
from the Västra Götaland Region. 
Finally, I would like to thank my family for their support 
and the inspiration they gave me to realize this huge goal. 
My dad, Sekhar, always by my side, even though you were 
hard on me on multiple occasions, in the end you always 
wanted me enjoy every moment in my life. My mother, 
Subbalakshmi, what can I say about you, it’s hard just to say 
thanks for everything you have given me. I will always be 
your little boy. My cousins here, Suman and Janani Akka, 
thanks for making me feel at home here. My cousin, Chaitu, 
and my mama, Ramana Reddy, for giving me the precious 
gift of life. Last but not least, I owe my deepest thanks to my 
wife, Srujana, for all your love, patience and support in my 
life. My son, Shriyan, together with you, I have experienced 
the most wonderful moments in my life. I “love you”. 
Sashidhar Bandaru 
Göteborg, November 2018 
51 
References 
1. Wang, K., J.F. Ash, and S.J. Singer,
Filamin, a new high-molecular-weight
protein found in smooth muscle and non-
muscle cells. Proc Natl Acad Sci U S A,
1975. 72: 4483–4496.
2. Guo, Y., et al., Physical and genetic
interaction of filamin with presenilin in
Drosophila. J Cell Sci, 2000. 113 Pt 19:
3499–3508.
3. van der Flier, A. and A. Sonnenberg,
Structural and functional aspects of
filamins. Biochim Biophys Acta, 2001.
1538: 99–117.
4. Lu, J., et al., Filamin B mutations cause
chondrocyte defects in skeletal
development. Hum Mol Genet, 2007. 16: 
1661–1675.
5. Zhou, X., J. Borén, and L.M. Akyürek,
Filamins in cardiovascular development.
Trends Cardiovasc Med, 2007. 17: 222–
229.
6. Stossel, T.P., et al., Filamins as
integrators of cell mechanics and
signalling. Nature Reviews Mol Cell Biol,
2001. 2: 138–145.
7. Zhou, A.X., J.H. Hartwig, and L.M.
Akyürek, Filamins in cell signaling,
transcription and organ development.
Trends Cell Biol, 2010. 20: 113–123.
8. Seo, M.D., et al., Crystal structure of the
dimerization domain of human filamin A.
Proteins, 2009. 75: 258–263.
9. Nakamura, F., et al., Structural basis of
filamin A functions. J Cell Biol, 2007. 179:
1011–1025.
10. Lebart, M.C., et al., Characterization of
the actin binding site on smooth muscle
filamin. J Biol Chem, 1994. 269: 4279–
4284.
11. Nakamura, F., T.P. Stossel, and J.H.
Hartwig, The filamins: organizers of cell
structure and function. Cell Adh Migr,
2011. 5(2): 160–169.
12. Lad, Y., et al., Structure of three tandem
filamin domains reveals auto-inhibition
of ligand binding. EMBO J, 2007. 26:
3993–4004.
13. Heikkinen, O.K., et al., Atomic structures
of two novel immunoglobulin-like
domain pairs in the actin cross-linking
protein filamin. J Biol Chem, 2009. 284:
25450–25458.
14. Gardel, M.L., et al., Prestressed F-actin
networks cross-linked by hinged filamins
replicate mechanical properties of cells.
Proc Natl Acad Sci U S A, 2006. 103:
1762–1767.
15. Fox, J.E., et al., Identification of two
proteins (actin-binding protein and
P235) that are hydrolyzed by
endogenous Ca2+-dependent protease
during platelet aggregation. J Biol Chem, 
1985. 260: 1060–1066.
16. Savoy, R.M. and P.M. Ghosh, The dual
role of filamin A in cancer: can't live with
(too much of) it, can't live without it.
Endocr Relat Cancer, 2013. 20: R341–
356.
17. Muller, M., et al., Localization of tissue
factor in actin-filament-rich membrane
areas of epithelial cells. Exp Cell Res,
1999. 248: 136–147.
18. Feng, Y.Y., et al., Filamin A (FLNA) is
required for cell-cell contact in vascular
development and cardiac
morphogenesis. Proc Natl Acad Sci U S A,
2006. 103: 19836–19841.
 52 
19. Cranmer, S.L., et al., High shear-
dependent loss of membrane integrity 
and defective platelet adhesion 
following disruption of the GPIbα-filamin 
interaction. Blood, 2011. 117: 2718–27. 
20. Lian, G.W., et al., Filamin A Regulates 
neural progenitor proliferation and 
cortical size through Wee1-Dependent 
Cdk1 phosphorylation. J Neurosci, 2012. 
32: 7672–7684. 
21. Nagano, T., et al., Filamin A-interacting 
protein (FILIP) regulates cortical cell 
migration out of the ventricular zone. 
Nat Cell Biol, 2002. 4: 495–501. 
22. Nagano, T., S. Morikubo, and M. Sato, 
Filamin a and FILIP (Filamin A-interacting 
protein) regulate cell polarity and 
motility in neocortical subventricular and 
intermediate zones during radial 
migration. J Neursci, 2004. 24: 9648–
9657. 
23. Lu, J., et al., Overlapping expression of 
ARFGEF2 and filamin a in the 
neuroependymal lining of the lateral 
ventricles: Insights into the cause of 
periventricular heterotopia. J Comp 
Neur, 2006. 494: 476–484. 
24. Gay, O., et al., RefilinB (FAM101B) 
targets filamin A to organize perinuclear 
actin networks and regulates nuclear 
shape. Proc Natl Acad Sci U S A, 2011. 
108: 11464–11479. 
25. Sarkisian, M.R., et al., MEKK4 signaling 
regulates filamin expression and 
neuronal migration. Neuron, 2006. 52: 
789–801. 
26. Zhong, Z., et al., Cyclin D1/cyclin-
dependent kinase 4 interacts with 
filamin A and affects the migration and 
invasion potential of breast cancer cells. 
Cancer Res, 2010. 70: 2105–2114. 
27. Loy, C.J., K.S. Sim, and E.L. Yong, Filamin-
A fragment localizes to the nucleus to 
regulate androgen receptor and 
coactivator functions. Proc Natl Acad Sci 
U S A, 2003. 100: 4562–4567. 
28. Ozanne, D.M., et al., Androgen receptor 
nuclear translocation is facilitated by the 
f-actin cross-linking protein filamin. Mol 
Endo, 2000. 14: 1618–1626. 
29. Meng, X., et al., Recovery from DNA 
damage-induced G2 arrest requires 
actin-binding protein filamin-A/actin-
binding protein 280. J Biol Chem, 2004. 
279: 6098–6105. 
30. van Vliet, A.R. and P. Agostinis, PERK 
interacts with FLNA to regulate ER-PM 
contact sites. Oncotarget, 2017. 8: 
106155–106156. 
31. Nallapalli, R.K., et al., Targeting filamin A 
reduces K-RAS–induced lung 
adenocarcinomas and endothelial 
response to tumor growth in mice. Mol 
Cancer, 2012. 11: 50. 
32. Maceyka, M., et al., Filamin A links 
sphingosine kinase 1 and sphingosine-1-
phosphate receptor 1 at lamellipodia to 
orchestrate cell migration. Mol Cell Biol, 
2008. 28: 5687–5697. 
33. Campos, L.S., et al., Filamin A expression 
negatively regulates sphingosine-1-
phosphate-induced NF-κB activation in 
melanoma cells by inhibition of Akt 
signaling. Mol Cell Biol, 2016. 36: 320–
329. 
34. Leonardi, A., et al., Physical and 
functional interaction of filamin (actin-
binding protein-280) and tumor necrosis 
factor receptor-associated factor 2. J Biol 
Chem, 2000. 275: 271–278. 
35. Campbell, I.D., Studies of focal adhesion 
assembly. Biochem Soc Trans, 2008. 36: 
263–266. 
36. Bellanger, J.M., et al., The Rac1-and 
RhoG-specific GEF domain of Trio targets 
filamin to remodel cytoskeletal actin. 
Nat Cell Biol, 2000. 2: 888–892. 
 53 
37. Urban, E., et al., Electron tomography 
reveals unbranched networks of actin 
filaments in lamellipodia. Nat Cell Biol, 
2010. 12: 429–435. 
38. Kim, H., et al., Filamin A regulates cell 
spreading and survival via β1 integrins. 
Exp Cell Res, 2008. 314: 834–846. 
39. Glogauer, M., et al., The role of actin-
binding protein 280 in integrin-
dependent mechanoprotection. J Biol 
Chem, 1998. 273: 1689–1698. 
40. Kim, H. and C.A. McCulloch, Filamin A 
mediates interactions between 
cytoskeletal proteins that control cell 
adhesion. Febs Letters, 2011. 585: 18–
22. 
41. Fox, J.W., et al., Mutations in filamin 1 
prevent migration of cerebral cortical 
neurons in human periventricular 
heterotopia. Neuron, 1998. 21: 1315–
1325. 
42. Hart, A.W., et al., Cardiac malformations 
and midline skeletal defects in mice 
lacking filamin A. Hum Mol Genet, 2006. 
15: 2457–2467. 
43. Lammermann, T., et al., Rapid leukocyte 
migration by integrin-independent 
flowing and squeezing. Nature, 2008. 
453: 51–55. 
44. Barry, N.P. and M.S. Bretscher, 
Dictyostelium amoebae and neutrophils 
can swim. Proc Natl Acad Sci U S A, 2010. 
107: 11376–11380. 
45. Loo, D.T., S.B. Kanner, and A. Aruffo, 
Filamin binds to the cytoplasmic domain 
of the β1-integrin. Identification of amino 
acids responsible for this interaction. J 
Biol Chem, 1998. 273: 23304–23312. 
46. Sharma, C.P., R.M. Ezzell, and M.A. 
Arnaout, Direct interaction of filamin 
(ABP-280) with the β2-integrin subunit 
CD18. J Immunol, 1995. 154: 3461–
3470. 
47. Calderwood, D.A., et al., Increased 
filamin binding to β-integrin cytoplasmic 
domains inhibits cell migration. Nat Cell 
Biol, 2001. 3: 1060–1068. 
48. Mammoto, A., S. Huang, and D.E. Ingber, 
Filamin links cell shape and cytoskeletal 
structure to Rho regulation by 
controlling accumulation of 
p190RhoGAP in lipid rafts. J Cell Sci, 
2007. 120: 456–467. 
49. Heuze, M.L., et al., ASB2 targets filamins 
A and B to proteasomal degradation. 
Blood, 2008. 112: 5130–5140. 
50. O'Connell, M.P., et al., Wnt5A activates 
the calpain-mediated cleavage of filamin 
A. J Invest Dermatol, 2009. 129: 1782–
1789. 
51. D'Addario, M., et al., Cytoprotection 
against mechanical forces delivered 
through β1 integrins requires induction 
of filamin A. J Biol Chem, 2001. 276: 
31969–31977. 
52. Meyer, S.C., D.A. Sanan, and J.E.B. Fox, 
Role of actin-binding protein in insertion 
of adhesion receptors into the 
membrane. J Biol Chem, 1998. 273: 
3013–3020. 
53. Xu, Y.J., et al., Filamin A regulates focal 
adhesion disassembly and suppresses 
breast cancer cell migration and 
invasion. J Expl Med, 2010. 207: 2421–
2437. 
54. Flevaris, P., et al., A molecular switch 
that controls cell spreading and 
retraction. J Cell Biol, 2007. 179(3): 553–
565. 
55. Franco, S.J., et al., Calpain-mediated 
proteolysis of talin regulates adhesion 
dynamics. Nat Cell Biol, 2004. 6: 977–
983. 
 
 
54 
56. Kim, H., et al., Regulation of cell
adhesion to collagen via β1 integrins is
dependent on interactions of filamin A
with vimentin and protein kinase C
epsilon. Exp Cell Res, 2010. 316: 1829–
1844.
57. Ohta, Y., et al., The small GTPase RalA
targets filamin to induce filopodia. Proc
Natl Acad Sci U S A, 1999. 96: 2122–
2128.
58. Vadlamudi, R.K., et al., Filamin is
essential in actin cytoskeletal assembly
mediated by p21-activated kinase 1. Nat
Cell Biol, 2002. 4: 681–690.
59. Pi, M., et al., Calcium-sensing receptor
activation of rho involves filamin and
rho-guanine nucleotide exchange factor.
Endocrinology, 2002. 143: 3830–3838.
60. Ohta, Y., J.H. Hartwig, and T.P. Stossel,
FilGAP, a Rho- and ROCK-regulated GAP
for Rac binds filamin A to control actin
remodelling. Nat Cell Biol, 2006. 8: 803–
814.
61. Sasaki, A., et al., Filamin associates with
Smads and regulates transforming
growth factor-β signaling. J Biol Chem,
2001. 276: 17871–17877.
62. Yoshida, N., et al., Filamin A-bound
PEBP2β/CBFβ is retained in the
cytoplasm and prevented from
functioning as a partner of the Runx1
transcription factor. Mol Cell Biol, 2005.
25: 1003–1012.
63. Kim, E.J., J.S. Park, and S.J. Um, Filamin A
negatively regulates the transcriptional
activity of p73α in the cytoplasm.
Biochem Biophys Res Commun, 2007.
362 : 1101–1106.
64. Yuan, Y. and Z. Shen, Interaction with
BRCA2 suggests a role for filamin-1
(hsFLNa) in DNA damage response. J Biol
Chem, 2001. 276: 48318–48324.
65. Berry, F.B., et al., FOXC1 transcriptional
regulatory activity is impaired by PBX1 in
a filamin A-mediated manner. Mol Cell
Biol, 2005. 25: 1415–1424.
66. Wang, Y., et al., A 90 kDa fragment of
filamin A promotes Casodex-induced
growth inhibition in Casodex-resistant
androgen receptor positive C4-2
prostate cancer cells. Oncogene, 2007.
26: 6061–6070.
67. Ozanne, D.M., et al., Androgen receptor
nuclear translocation is facilitated by the
f-actin cross-linking protein filamin. Mol
Endocrinol, 2000. 14: 1618–1626.
68. Bruick, R.K., Oxygen sensing in the
hypoxic response pathway: regulation of
the hypoxia-inducible transcription
factor. Genes Dev, 2003. 17: 2614–2623.
69. Bracken, C.P., M.L. Whitelaw, and D.J.
Peet, The hypoxia-inducible factors: key
transcriptional regulators of hypoxic
responses. Cell Mol Life Sci, 2003. 60:
1376–1393.
70. Pugh, C.W. and P.J. Ratcliffe, Regulation
of angiogenesis by hypoxia: role of the
HIF system. Nat Med, 2003. 9: 677–684.
71. Ferrara, N., H.P. Gerber, and J. LeCouter,
The biology of VEGF and its receptors.
Nat Med, 2003. 9: p. 669–676.
72. Zheng, X., et al., Hypoxia-induced and
calpain-dependent cleavage of filamin A
regulates the hypoxic response. Proc
Natl Acad Sci U S A, 2014. 111: 2560–
2565.
73. Zhou, A.X., et al., Filamin a mediates
HGF/c-MET signaling in tumor cell
migration. Int J Cancer, 2011. 128: 839–
846.
74. Birchmeier, C., et al., Met, metastasis,
motility and more. Nat Rev Mol Cell Biol,
2003. 4: 915–925.
55 
75. Zhang, Y.W. and G.F. Vande Woude,
HGF/SF-met signaling in the control of
branching morphogenesis and invasion.
J Cell Biochem, 2003. 88: 408–417.
76. Wegenka, U.M., et al., Acute-Phase
Response Factor, a Nuclear Factor
Binding to Acute-Phase Response
Elements, Is Rapidly Activated by
Interleukin-6 at the Posttranslational
Level. Mol Cellular Biol, 1993. 13: 276–
288.
77. Takeda, K., et al., Targeted disruption of
the mouse Stat3 gene leads to early
embryonic lethality. Proc Natl Acad Sci U
S A, 1997. 94: 3801–3804.
78. Levy, D.E. and C.K. Lee, What does Stat3
do? J Clin Invest, 2002. 109: 1143–1148.
79. Guschin, D., et al., A major role for the
protein tyrosine kinase JAK1 in the
JAK/STAT signal transduction pathway in
response to interleukin-6. EMBO J, 1995.
14: 1421–1429.
80. Benekli, M., et al., Signal transducer and
activator of transcription proteins in
leukemias. Blood, 2003. 101: 2940–
2954.
81. Dutzmann, J., et al., Emerging
translational approaches to target
STAT3 signalling and its impact on
vascular disease. Cardiovasc Res, 2015.
106: 365–374.
82. Harada, M., et al., G-CSF prevents
cardiac remodeling after myocardial
infarction by activating the Jak-Stat
pathway in cardiomyocytes. Nat Med,
2005. 11: 305–311.
83. Hilfiker-Kleiner, D., et al., Signal
transducer and activator of transcription
3 is required for myocardial capillary
growth, control of interstitial matrix
deposition, and heart protection from
ischemic injury. Circ Res, 2004. 95: 187–
195.
84. Zhou, X.X., et al., Pravastatin prevents
aortic atherosclerosis via modulation of
signal transduction and activation of
transcription 3 (STAT3) to attenuate
interleukin-6 (IL-6) action in ApoE
knockout mice. Int J Mol Sci, 2008. 9:
2253–2264.
85. Ridker, P.M., et al., Plasma
concentration of interleukin-6 and the
risk of future myocardial infarction
among apparently healthy men.
Circulation, 2000. 101: 1767–1772.
86. Gan, A.M., et al., Monocytes and smooth
muscle cells cross-talk activates STAT3
and induces resistin and reactive oxygen
species production. J Cell Biochem, 2013. 
114: 2273–2283.
87. Loppnow, H., et al., Statins potently
reduce the cytokine-mediated IL-6
release in SMC/MNC cocultures. J Cell
Mol Med, 2011. 15: 994–1004.
88. Sorimachi, H., S. Hata, and Y. Ono,
Impact of genetic insights into calpain
biology. J Biochem, 2011. 150: 23–37.
89. Sorimachi, H., S. Hata, and Y. Ono,
Expanding Members and Roles of the
Calpain Superfamily and Their
Genetically Modified Animals. Exp
Animals, 2010. 59: 549–566.
90. Ohno, S., et al., Evolutionary Origin of a
Calcium-Dependent Protease by Fusion
of Genes for a Thiol Protease and a
Calcium-Binding Protein. Nature, 1984.
312: 566–570.
91. Davies, P.J., et al., Filamin-actin
interaction. Dissociation of binding from
gelation by Ca2+-activated proteolysis. J
Biol Chem, 1978. 253: 4036–4042.
92. Hemmings, L., et al., Talin contains three
actin-binding sites each of which is
adjacent to a vinculin-binding site. J Cell
Sci, 1996. 109: 2715–2726.
 56 
93. Arthur, J.S., et al., Disruption of the 
murine calpain small subunit gene, 
Capn4: calpain is essential for embryonic 
development but not for cell growth and 
division. Mol Cell Biol, 2000. 20: 4474–
4481. 
94. Kishimoto, A., et al., Limited proteolysis 
of protein kinase C subspecies by 
calcium-dependent neutral protease 
(calpain). J Biol Chem, 1989. 264: 4088–
4092. 
95. Kidd, V.J., J.M. Lathi, and T. Teitz, 
Proteolytic regulation of apoptosis. Sem  
Cell  Dev Bio, 2000. 11: 191–201. 
96. Pariat, M., et al., The sensitivity of c-Jun 
and c-Fos proteins to calpains depends 
on conformational determinants of the 
monomers and not on formation of 
dimers. Biochem J, 2000. 345: 129–138. 
97. Watanabe, N., et al., Specific Proteolysis 
of the C-Mos Proto-Oncogene Product by 
Calpain on Fertilization of Xenopus Eggs. 
Nature, 1989. 342: 505–511. 
98. Donkor, I.O., An updated patent review 
of calpain inhibitors (2012 - 2014). 
Expert Opin Ther Pat, 2015. 25: 17–31. 
99. Ozaki, T., et al., Intravitreal injection or 
topical eye-drop application of a mu-
calpain C2L domain peptide protects 
against photoreceptor cell death in 
Royal College of Surgeons' rats, a model 
of retinitis pigmentosa. Biochim Biophys 
Acta, 2012. 1822: 1783–1795. 
100. Sanderson, J., J.M. Marcantonio, and G. 
Duncan, A human lens model of cortical 
cataract: Ca2+-induced protein loss, 
vimentin cleavage and opacification. 
Invest Ophthalmol Vis Sci, 2000. 41: 
2255–2261. 
101. Lee, E., et al., Neuroprotective effect of 
undecylenic acid extracted from Ricinus 
communis L. through inhibition of µ-
calpain. Eur J Pharm Sci, 2012. 46: 17–
25. 
102. Baghdiguian, S., et al., Calpain 3 
deficiency is associated with myonuclear 
apoptosis and profound perturbation of 
the IκBα/NF-κB pathway in limb-girdle 
muscular dystrophy type 2A. Nat Med, 
1999. 5: 503–511. 
103. Ilian, M.A., R.S. Gilmour, and R. 
Bickerstaffe, Quantification of ovine and 
bovine calpain I, calpain II, and 
calpastatin mRNA by ribonuclease 
protection assay. J Anim Sci, 1999. 77: 
853–864. 
104. Inserte, J., V. Hernando, and D. Garcia-
Dorado, Contribution of calpains to 
myocardial ischaemia/reperfusion 
injury. Cardiovasc Res, 2012. 96: 23–31. 
105. Cunningham, C.C., et al., Actin-binding 
protein requirement for cortical stability 
and efficient locomotion. Science, 1992. 
255: 325–337. 
106. Retailleau, K., et al., Smooth muscle 
filamin A is a major determinant of 
conduit artery structure and function at 
the adult stage. Pflugers Arch, 2016. 
468: 1151–1160. 
107. Begonja, A.J., et al., FlnA-null 
megakaryocytes prematurely release 
large and fragile platelets that circulate 
poorly. Blood, 2011. 118: 2285–2295. 
108. Leung, R., et al., Filamin A regulates 
monocyte migration through Rho small 
GTPases during osteoclastogenesis. J 
Bone Miner Res, 2010. 25: 1077–1091. 
109. Disease, G.B.D., I. Injury, and C. 
Prevalence, Global, regional, and 
national incidence, prevalence, and 
years lived with disability for 310 
diseases and injuries, 1990-2015: A 
systematic analysis for the Global 
Burden of Disease Study 2015. Lancet, 
2016. 388: 1545–1602. 
 57 
110. Van de Werf, F., et al., Management of 
acute myocardial infarction in patients 
presenting with persistent ST-segment 
elevation: the Task Force on the 
Management of ST-Segment Elevation 
Acute Myocardial Infarction of the 
European Society of Cardiology. Eur 
Heart J, 2008. 29: 2909–2945. 
111. Buja, L.M., Myocardial ischemia and 
reperfusion injury. Cardiovasc Pathol, 
2005. 14: 170–175. 
112. Kutty, R.S., N. Jones, and N. Moorjani, 
Mechanical complications of acute 
myocardial infarction. Cardiol Clin, 2013. 
31: 519–531. 
113. O'Gara, P.T., et al., 2013 ACCF/AHA 
guideline for the management of ST-
elevation myocardial infarction: A report 
of the American College of Cardiology 
Foundation/American Heart Association 
Task Force on Practice Guidelines. 
Circulation, 2013. 127: e362–425. 
114. Sumpio, B.E., J.T. Riley, and A. Dardik, 
Cells in focus: endothelial cell. Int J 
Biochem Cell Biol, 2002. 34: 1508–1512. 
115. Sasayama, S. and M. Fujita, Recent 
insights into coronary collateral 
circulation. Circulation, 1992. 85: 1197–
1204. 
116. Hansson, G.K., Inflammatory 
mechanisms in atherosclerosis. J Thromb 
Haemost, 2009. 7 Suppl 1: 328–331. 
117. Hansson, G.K., Atherosclerosis--an 
immune disease: The Anitschkov Lecture 
2007. Atherosclerosis, 2009. 202: 2–10. 
118. Wick, G. and Q, Xu., Atherosclerosis--an 
autoimmune disease. Exp Gerontol, 
1999. 34: 559–566. 
119. Ross, R. and J.A. Glomset, 
Atherosclerosis and the arterial smooth 
muscle cell: Proliferation of smooth 
muscle is a key event in the genesis of the 
lesions of atherosclerosis. Science, 1973. 
180: 1332–1339. 
120. Williams, K.J. and I. Tabas, The response-
to-retention hypothesis of atherogenesis 
reinforced. Curr Opin Lipidol, 1998. 9: 
471–474. 
121. Williams, K.J. and I. Tabas, The response-
to-retention hypothesis of early 
atherogenesis. Arterioscler Thromb Vasc 
Biol, 1995. 15: 551–561. 
122. Ross, R., Atherosclerosis--an 
inflammatory disease. N Engl J Med, 
1999. 340: 115–126. 
123. Ovchinnikov, D.A., Macrophages in the 
embryo and beyond: Much more than 
just giant phagocytes. Genesis, 2008. 46: 
447–462. 
124. Oh, J., et al., Endoplasmic reticulum 
stress controls M2 macrophage 
differentiation and foam cell formation. 
J Biol Chem, 2012. 287: 11629–11641. 
125. Saric, M. and I. Kronzon, Aortic 
atherosclerosis and embolic events. Curr 
Cardiol Rep, 2012. 14: 342–349. 
126. Robertson, S.P., et al., 
Frontometaphyseal dysplasia: 
Mutations in FLNA and phenotypic 
diversity. Am J Med Gen A, 2006. 140: 
2840–2840. 
127. Robertson, S.P., et al., Localized 
mutations in the gene encoding the 
cytoskeletal protein filamin A cause 
diverse malformations in humans. Nat 
Gen, 2003. 33: 487–491. 
128. Feng, Y. and C.A. Walsh, The many faces 
of filamin: a versatile molecular scaffold 
for cell motility and signalling. Nat Cell 
Biol, 2004. 6: 1034–1138. 
129. Kyndt, F., et al., Mutations in the gene 
encoding filamin A as a cause for familial 
cardiac valvular dystrophy. Circulation, 
2007. 115: 40–49. 
58 
130. Parrini, E., et al., Periventricular
heterotopia: phenotypic heterogeneity
and correlation with Filamin A
mutations. Brain, 2006. 129: 1892–1906.
131. Sheen, V.L., et al., Filamin A mutations
cause periventricular heterotopia with
Ehlers-Danlos syndrome. Neurology,
2005. 64: 254–262.
132. Khan, O.M., et al., Targeting GGTase-I
activates RHOA, increases macrophage
reverse cholesterol transport, and
reduces atherosclerosis in mice.
Circulation, 2013. 127:782–790.
133. Tian, F., et al., Endothelial cells are
activated during hypoxia via 
endoglin/ALK-1/SMAD1/5 signaling in 
vivo and in vitro. Biochem Biophys Res 
Commun, 2010. 392: 283–238. 
134. Tian, F., et al., Protein disulfide
isomerase increases in myocardial
endothelial cells in mice exposed to
chronic hypoxia: a stimulatory role in
angiogenesis. Am J Physiol Heart Circ
Physiol, 2009. 297: H1078–1086.
135. Fagerberg, B., et al., Differences in lesion
severity and cellular composition
between in vivo assessed upstream and
downstream sides of human
symptomatic carotid atherosclerotic
plaques. J Vasc Res, 2010. 47: 221–230.
136. Ekstrand, M., et al., Depletion of ATP and
glucose in advanced human
atherosclerotic plaques. PLoS One, 2017.
12: e0178877.
137. Alva, J.A., et al., VE-Cadherin-Cre-
recombinase transgenic mouse: a tool
for lineage analysis and gene deletion in
endothelial cells. Dev Dyn, 2006. 235:
759–767.
138. Clausen, B.E., et al., Conditional gene
targeting in macrophages and
granulocytes using LysMcre mice.
Transgenic Res, 1999. 8: 265–277.
139. Lundqvist, A., et al., Oregonin reduces
lipid accumulation and proinflammatory
responses in primary human 
macrophages. Biochem Biophys Res 
Commun, 2015. 458: p. 693–699. 
140. Bandaru, S., et al., Deficiency of filamin A
in endothelial cells impairs left
ventricular remodelling after myocardial
infarction. Cardiovasc Res, 2015. 105:
151–159.
141. Sayin, V.I., et al., Loss of one copy of
Zfp148 reduces lesional macrophage
proliferation and atherosclerosis in mice
by activating p53. Circ Res, 2014. 115:
781–789.
142. Björklund, M.M., et al., Induction of
atherosclerosis in mice and hamsters
without germline genetic engineering.
Circ Res, 2014. 114: 1684–1692.
143. Ho, V.C., et al., Elevated vascular
endothelial growth factor receptor-2
abundance contributes to increased
angiogenesis in vascular endothelial
growth factor receptor-1-deficient mice.
Circulation, 2012. 126: 741–752.
144. Wang, Y., et al., Ephrin-B2 controls VEGF-
induced angiogenesis and
lymphangiogenesis. Nature, 2010. 465:
483–486.
145. Li, A.C. and C.K., Glass, The macrophage
foam cell as a target for therapeutic
intervention. Nat Med, 2002. 8: 1235–
1242.
146. Akita, K., et al., An interleukin-6 receptor
antibody suppresses atherosclerosis in
atherogenic mice. Front Cardiovasc
Med, 2017. 4: 84.
147. Cheng, F., et al., A critical role for STAT3
signaling in immune tolerance.
Immunity, 2003. 19: 425–436.
